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ABSTRACT 
Background: The prevalence of differentiated thyroid cancer (DTC) is increasing as a consequence 
of rising incidence, young age at diagnosis and excellent survival. The established treatment is 
surgery, followed by radioiodine as well as levothyroxine substitution. Because of the longevity of 
DTC patients, health-related quality of life (HRQoL) has become important. Previous studies have 
shown decreased HRQoL in DTC, nevertheless, changes of HRQoL over time and factors affecting 
HRQoL are scarcely described. The aims of this thesis were to investigate long-term HRQoL, how 
HRQoL changes over time and how anxiety and fear of recurrence affect patients with thyroid cancer.   
Patients, methods and results: In Studies I-III, SF-36 and a study-specific questionnaire were used. 
In Studies I-II, long-term HRQoL was measured by including patients 14-17 years after diagnosis. 
HRQoL was shown to be lower in DTC patients compared with the Swedish general population. Half 
of the patients had fear of recurrence, and those with fear had significantly lower HRQoL. Thyroid-
related symptoms, such as fatigue, sleeping problems, irritability and sweating were measured, and the 
majority (88%) had at least one of these symptoms. Those with major or moderate symptom intensity 
had significantly lower HRQoL in eight and four SF-36 domains, respectively. These differences 
remained after adjustment for age, sex, comorbidities and education. 
In study III, DTC patients were included at diagnosis and followed-up. After one year, HRQoL was 
higher compared with baseline in six of eight SF-36 domains. As the majority of the patients were 
treated with levothyroxine in TSH suppressive doses, this might have affected HRQoL. Surprisingly, 
those on moderate TSH suppression had lower HRQoL compared with those on complete 
suppression. In addition, more than half of the patients had a fear of recurrence, with significantly 
lower HRQoL. Predictive factors of HRQoL at follow-up were studied and in bivariate models, e.g. 
comorbidities and HRQoL at diagnosis were associated with lower HRQoL at one year. In regression 
models, poor HRQoL at diagnosis was the only predictive factor for poor HRQoL at one-year of 
follow-up, after adjustment for comorbidities, age, sex, stage of disease and fear of recurrence. 
To broaden the understanding about anxiety and fear of recurrence, semi-structured interviews were 
performed with 21 patients in Study IV. Anxiety was present both in patients with and without 
recurrence and regardless of sociodemographic factors. Fear of recurrence, follow-up routines, distrust 
in the healthcare system and lack of information were all sources of anxiety. In some patients, hidden 
anxiety not mentioned in the beginning became apparent later during the interviews. Everyday life and 
routines were used as protective strategies against frightening thoughts. Avoiding contact with 
healthcare helped them gather energy to cope with their disease. 
Discussion: HRQoL was decreased in DTC patients compared with a general population and was 
negatively associated with thyroid-related symptoms and fear of recurrence. Interestingly, TSH 
suppression was not associated to lower HRQoL. The patients’ perception of having a “good cancer” 
might have discouraged them from discussing anxiety with healthcare. As HRQoL at diagnosis was 
the only independent predictive factor of HRQoL at one year of follow-up, the evaluation of HRQoL 
early in the disease trajectory is important. Individualised follow-up routines and evaluation of fears 
and anxiety during consultations might be helpful, and instead of using the term “good cancer”, “low-
risk cancer” can be recommended. 
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1 INTRODUCTION 
“Lena is a 40-year-old woman. She was diagnosed with a small papillary thyroid cancer four 
years ago. Initially, she had an operation followed by radioiodine treatment, since then, her 
levothyroxine dose has been on a therapeutic level and there have been no signs of 
recurrence. Nonetheless, she has developed an intricate anxiety concerning the healthcare 
system. Some weeks before her follow-up visit she feels severe anxiety, and experiences 
sleeping problems and difficulties at work. When it is time for the visit, she can barely make it 
to the parking area. Several times, she has cancelled the consultation and not taken the 
recommended laboratory tests.”   
For healthcare professionals Lena is free of cancer, with an excellent prognosis. So why has 
she been so affected by the disease? My personal interest in understanding the effect of 
thyroid cancer on patients’ quality of life and how the disease can influence their lives was 
the starting point for this thesis.  
Thyroid cancer is the most common endocrine cancer and the incidence is rapidly increasing 
worldwide. The disease affects people of all ages, but in contrast to many other cancers, the 
majority of patients are diagnosed before 50 years of age. The overall survival is regarded as 
good, but with a risk of recurrence that remains for decades. 
As the majority of patients with thyroid cancer will live for many years with the 
consequences of treatment and follow-up, their long-term quality of life becomes of great 
importance. Most patients will receive long-term treatment with thyroid hormones, both in 
high doses to decrease the risk of recurrence and to replace the hormone production of the 
thyroid gland after surgery. As thyroid hormones affect the metabolism of all human cells, 
the understanding of hormonal production and regulation is essential to understand. 
Therefore, side-effects from thyroid hormones might affect health-related quality of life 
(HRQoL) and, in addition, surgery and radioiodine treatments might give symptoms affecting 
HRQoL. 
Receiving a cancer diagnosis is, moreover, life changing, and can be even more 
overwhelming when it is received at a young age. Because of the life-long thyroid hormone 
treatment and recurrence risk, some form of follow-up is paramount for the rest of the 
patients’ lives. To be reminded of the cancer diagnosis both daily when taking medication, 
and regularly during medical follow-up, also insures that the disease cannot be forgotten. 
Thus, HRQoL might be negatively affected in thyroid cancer patients due to several reasons. 
Indeed, little is known about long-term HRQoL in thyroid cancer, which factors might affect 
it and how it changes over time.  
This thesis aimed to study HRQoL in thyroid cancer, both prospectively after the primary 
treatment, and after many years of follow-up, using both a validated general questionnaire 
and a disease-specific questionnaire. The study-specific questionnaire was developed, 
because no disease-specific questionnaire was available in Swedish. In addition, semi-
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structured qualitative interviews were used, to find unknown factors important for HRQoL in 
thyroid cancer. 
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2 BACKGROUND 
2.1 THYROID ANATOMY 
The thyroid gland is the largest single organ specialised for endocrine hormone production 
and is located on the anterolateral aspect of the cricothyroid and the trachea 
1
. The name 
thyroid is derived from ancient Greek, which means shield-like, which is related to its 
relationship to the laryngeal thyroid cartilage, shaped like a shield 
2
.  The main function is to 
produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3) 
3
. Anatomically, the 
thyroid gland consists of two lobes, connected by a thinner tissue band called the isthmus, 
and is surrounded by a capsule. The normal weight of the thyroid gland ranges from 15-25 g 
in adults, depending on iodine supply, sex and body weight 
1
. It has a rich blood supply from 
the superior and inferior thyroid arteries. The first lymphatic drainage is mainly to the central 
compartment followed by the lateral neck compartments. The recurrent laryngeal nerves run 
in close relationship to the thyroid gland and the parathyroid glands are located on its dorsal 
surface 
1,4,5
. 
The thyroid gland is composed histologically of two main parenchymal cell types; thyroid 
follicular and parafollicular, or C cells. The thyroid follicular cells, or thyroid cells, form 
follicles, spherical structures, which are the functional units of the thyroid. The thyroid cells 
and the follicles are responsible for concentrating iodine, and the production, storage and 
secretion of thyroid hormones 
3-5
. The parafollicular cells are the source of calcitonin, a 
hormone that is regulating calcium homeostasis, but with no apparent physiological role in 
humans 
6
. 
2.2 THYROID PHYSIOLOGY 
The thyroid hormones thyroxine (T4) and triiodothyronine (T3) are synthesised by the 
follicular cells of the thyroid gland and iodine is required for the synthesis. Thyroid hormone 
activity is regulated by the hypothalamic-pituitary-thyroid-peripheral tissue axis. The 
hypothalamus secretes thyrotropin-releasing hormone (TRH), which stimulates the anterior 
pituitary gland to release the thyroid-stimulating hormone (TSH) and TSH stimulates the 
synthesis of thyroid hormones. A negative feedback system is regulating hormone 
production, where T3 and T4 decrease the release of TRH and TSH 
3
. Clinically, TSH is the 
single most useful measurement in the evaluation of thyroid function 
4
 while TSH stimulates 
thyroid cell growth, the biosynthesis of thyroid hormones, increases iodine uptake and 
stimulates the secretion of thyroid hormones 
3
.  
Iodine, an essential nutrient received from the diet, is the corner-stone of thyroid hormone 
production. At the basolateral membrane of the follicular cells iodine is actively transported 
into the thyroid cells by the sodium-iodine symporter (NIS). At the apical membrane-colloid 
interface of the thyroid cells, iodine becomes a substrate for thyroid hormonogenesis. In 
addition, follicular cells produce a glycoprotein called Thyroglobulin (Tg), which serves as a 
matrix for the synthesis of the thyroid hormones. The thyroid hormones are stored in the 
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follicular lumen attached to the Tg. Under TSH stimulation, Tg is transported back into the 
thyroid cells and T4 and T3 are secreted into the bloodstream. The released iodine is recycled 
for hormone synthesis. Smaller amounts of Tg is released from the thyroid and circulates in 
blood 
4,5
. In thyroid cancer derived from the epithelial cells, Tg is excreted in larger amounts 
and can thus be used as a sensitive tumour marker during follow-up 
3
.  
The main hormone secreted to the blood stream is T4, and T3 is mainly produced by extra 
thyroidal deiodination of T4, particularly in the liver and kidneys. The thyroid hormones are 
important for nearly all cells in the human body, and are fundamental for central nervous 
system development, body growth, thermoregulation, weight, lipid metabolism, regulation of 
heart rate and myocardial contraction and relaxation. Additionally, they affect gastrointestinal 
motility and renal water clearance 
4
. 
2.3 DIFFERENTIATED THYROID CANCER 
Thyroid nodules are very common, about 4-7% of adults have a palpable thyroid nodule and 
approximately 5-30% of those will be malignant. Thyroid follicular cells give rise to 
differentiated thyroid cancer (DTC), i.e. papillary (PTC) and follicular (FTC) thyroid cancer 
and, in addition, anaplastic thyroid cancer (ATC). Poorly differentiated thyroid carcinoma is a 
rare epithelial-derived tumour which lacks the characteristics of PTC 
7
.  
DTC represents the most common type of thyroid carcinoma, accounting for more than 90% 
of all thyroid cancers 
6
. ATC is regarded as the most aggressive solid tumour, with a median 
survival of only five months 
8
. The prognosis for poorly differentiated thyroid carcinoma is 
between PTC and ATC 
9
. Medullary thyroid cancer (MTC), rising from the parafollicular 
cells, accounts for 3-5% of thyroid carcinomas and has a genetic predisposition in about 20% 
of cases 
6
. Although they are rare, metastases from other cancers and lymphomas occur in the 
thyroid and should be considered during the diagnosis of thyroid nodules 
7
. 
2.3.1 Papillary thyroid cancer 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and 
accounts for more than 80% of all thyroid carcinomas 
10
. Fine needle aspiration cytology 
(FNAC) is conclusive in the majority of patients 
11
. Lymph node metastases occur in about 
20-80% of all PTCs at diagnosis and can be the presenting symptom of PTC 
6
. The tumours 
are often multifocal and, in addition, have extrathyroidal extension 
12
. Tumours less than 1 
cm in diameter are defined as micro-carcinomas. Although the prognosis is good, distant 
metastases occur, and lungs and bone are the most common localisations 
6
. 
2.3.2 Follicular thyroid cancer 
Follicular thyroid carcinoma (FTC) comprises 5-15% of all thyroid carcinomas. It is a 
malignant epithelial tumour but lacks the diagnostic features of PTC 
7
. The diagnosis is not 
possible by FNAC and a histological sample is required for diagnosis 
11
. FTC is separated 
histologically into two main groups: minimally invasive and widely invasive. The minimally 
invasive FTC has minimal capsular and vascular invasion while widely invasive FTC has 
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apparent vascular and/or capsular invasion. Lymph node metastases seldom occur and distant 
metastases are predominately found in the lungs, bone and brain. The prognosis is clearly 
worse for widely invasive tumours. Oncocytic carcinomas, or Hürthle cell carcinomas, are a 
variant of FTC and more common in older patients. These tumours more often metastasise to 
lymph nodes and also to bone and lungs. Higher rates of follicular carcinomas have been seen 
in areas with iodine deficiency, with an incidence of 20-40% of all thyroid carcinomas 
7
. 
2.3.3 Epidemiology of thyroid cancer 
In Sweden, thyroid cancer accounts for approximately 1% of all cancer diagnoses and more 
than 600 new cases were diagnosed in 2015 
13
. It is the most common endocrine cancer and 
its incidence is rising both in Sweden and worldwide 
14,15
. More than half of the patients are 
diagnosed before the age of 50 and thyroid cancer is two to three times more common in 
women 
13
. The incidence in Sweden was 7/100,000 in 2015 compared with 3.4/100,000 10 
years earlier 
14
, and the incidence has been rising since 1970 with a more pronounced 
increase over the last decade 
16
. In the United States, thyroid cancer is now the fifth leading 
cause of cancer in women, accounting for 5% 
17
. It is also suggested that it will be the third 
most common cancer in women of all ages, and the second most common cancer in women 
younger than 45 years of age, in the United States by 2019 
18
. This is mainly related to the 
growing incidence of small PTCs, and the rising incidence has been suspected to be related to 
better diagnostic procedures and screening 
19
. However, a recent study showed an increase in 
advanced-stage papillary thyroid cancers and a simultaneous increase in mortality in the 
United States. Thus, this indicates a true increase in thyroid cancer 
15
.  
Radiation exposure during childhood is the only established risk factor for thyroid cancer 
20
. 
After the nuclear power accident in Chernobyl a large number of childhood thyroid 
carcinomas were reported 
21
. Inhalation of radioactive iodine and the consumption of 
contaminated milk cause DNA damage 
22
, which leads to an increased risk of thyroid cancer 
21
. Moreover, treatment with external radiation under the age of 20 increases the risk of 
thyroid cancer 
23,24
. Radiation-induced PTCs are unique, as most tumours have RET/PTC 
chromosomal rearrangements. BRAF point mutations, found in sporadic PTC, occur rarely in 
radiation induced PTC 
25
. 
In iodine-deficient areas there may be more follicular carcinomas and fewer PTCs, but the 
total amount of thyroid carcinomas does not seem to be affected by iodine intake 
26
. There are 
no other conclusive risk factors although, for example, weight gain 
27
, obesity, oestrogen and 
diabetes have been suggested as causes increasing the risk of thyroid cancer 
28
. 
2.3.4 Symptoms and diagnosis 
The most common presenting symptom is a lump in the neck, either from the thyroid tumour 
or from lymph node metastases. More seldom, hoarseness, difficulties swallowing or 
symptoms from distant metastases are the first symptoms 
1
. Ultrasound is the most 
appropriate radiological method when investigating the thyroid and loco-regional lymph 
nodes. Computerised tomography might be used, but contrast media with iodine should be 
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avoided when radioiodine treatment might be needed during treatment. Magnetic resonance 
imaging is of importance if local growth into surrounding organs is suspected 
7
.  
Fine needle aspiration cytology (FNAC) is conclusive in the majority of PTCs. Diagnosis of 
FTC needs a histological specimen, while growth into vessels or capsule cannot be seen in 
FNAC and surgery is warranted in follicular tumours 
29
. 
2.3.5 Staging and prognosis 
Thyroid cancer is classified according to the TNM classification 
30
: tumour size and 
invasiveness (T), lymph node metastases (N) and presence of distant metastases (M) and a 
new TNM classification has recently been introduced 
31
. Based on the TNM classification, 
thyroid cancer is divided into risk groups according to recurrence risk: very low, low or high 
risk, with smaller differences between the American Thyroid Association (ATA) 
32
 and 
European Thyroid Association (ETA) 
33,34
. The Swedish national recommendations 
35
 have 
adjusted treatment recommendations according to the international guidelines. In addition, 
based on the outcome of the initial treatment, patients are re-classified into four response 
categories (i.e., excellent, intermediate, biochemical incomplete, and structural incomplete), 
on the basis of the findings during follow-up 
32
.  
The prognosis of DTC is good, with a 10-year survival of more than 90% 
36
. High survival 
rates are seen especially in patients with small PTCs, while older patients, those with larger 
tumours and widely invasive FTC have lower survival rates 
6,31
. Although survival is high, 
25-30 % of patients develop loco-regional recurrence, which can occur as long as 30 years 
after diagnosis 
37,38
. The rising incidence in combination with young age at diagnosis and the 
excellent prognosis is resulting in a high prevalence in thyroid cancer survivors and about 
8000 patients live with thyroid cancer in Sweden 
39
. 
2.3.6 Treatment of differentiated thyroid cancer 
The treatment of DTC is not considered as aggressive as the treatment for many other 
cancers. The main treatment is surgery, followed by radioiodine and levothyroxine treatment.  
In selected cases, external radiotherapy might be indicated and tyrosine kinase inhibitors are 
an option in metastatic disease 
32
. 
Surgical treatment 
The preferred surgical treatment of DTC is thyroidectomy in combination with lymph node 
dissection when appropriate. If PTC is diagnosed pre-operatively, total thyroidectomy is 
preferred in all cases except for those with a tumour <1cm, then hemithyroidectomy can be 
recommended. In follicular tumours, hemithyroidectomy is preferred, to enable a correct 
diagnosis based on histopathology 
32
 followed by a completion of the other side if 
invasiveness is observed. Prophylactic central lymph node dissection is debated. The risk of 
complications might be higher than the benefit, when it comes to reducing recurrences 
40
. 
According to the international guidelines the aims of surgical treatment are;  
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I) to remove the primary tumour and involved lymph nodes, in order to decrease 
recurrence and metastatic spread 
II) to facilitate postoperative treatment with radioactive iodine 
III) to permit accurate long-term surveillance with whole-body scanning (WBS) and Tg 
measurement  
Adequate surgery is the most important treatment influencing prognosis, while radioactive 
iodine, TSH suppression, and external beam radiation play an adjunctive role 
32
. Possible 
complications from surgery are recurrent laryngeal nerve injury with vocal cord palsy or 
dysphonia, hypoparathyroidism or bleeding. Post-operative hypoparathyroidism is often 
reversible, but is life-long in 0.9-1.6% of patients and requires vitamin D and/or calcium 
supplementation 
41
. Dysphonia is reversible in more than 90% of the patients but can give 
life-long hoarseness 
42
. 
Radioiodine treatment 
Radioiodine (RAI) treatment with 
131
I is indicated both post-operatively and in metastatic 
disease. The initial 
131
I treatment of DTC patients after total thyroidectomy is divided into 
ablation, adjuvant therapy, and the therapy of persistent disease. The aim of post-operative 
ablation is to eradicate persistent normal thyroid tissue to enable adequate follow-up. 
Adjuvant therapy, in addition to ablation, is intended to destroy possible, but not proven, 
residual disease to decrease the risk of recurrence. RAI therapy is intended to increase 
survival by treating persistent disease. The RAI treatment enables proper follow-up with 
WBS and measurement of the tumour marker Tg, while the normal thyroid tissue to a lesser 
extent is visible on WBS and the measured Tg reflects tumour activity instead of normal 
thyroid tissue. RAI treatment is avoided in low-risk patients, in which the benefit for 
recurrence and survival has not been proven 
32
. A more selective use with both lower doses 
and an increase in the number of patients not recommended RAI has been seen over the last 
few years, in order to decrease the risk of side-effects 
43
. 
The effect of RAI is based on the ability of iodine uptake of the thyroid cells by the sodium-
iodine symporter (NIS), with the same mechanism as dietary iodine. Stimulation by TSH is 
needed to promote iodine uptake by thyroid cells, while the NIS have lesser activity in 
thyroid cancer cells compared with normal thyroid cells. The TSH stimulation is achieved 
either through thyroid hormone withdrawal (THW) for three to five weeks, or the 
administration of recombinant human TSH (rhTSH) 
32
. When TSH is high, the expression of 
NIS rises which increases iodine uptake and makes radioiodine treatment more efficient 
44
. 
Similar efficacy between THW and rhTSH has been demonstrated for post-operative thyroid 
ablation 
45,46
, with lesser side-effects for rhTSH. The drawback of rhTSH is the high costs, 
and the cost effectiveness of its administration has not been proven 
47
. Treatment activity 
depends on the aim of the treatment, with lower activities (1.1 GBq) in ablation and higher 
activities (3.7-7.4 GBq) in adjuvant and therapy indication. Even higher activities might be 
delivered with the use of dosimetry 
48
. 
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Side-effects from RAI treatment include symptoms from salivary glands with both acute 
sialoadenitis 
49
 and persisting xerostomia 
50-52
. Transient gonadal function disturbances are 
described both in men and women 
53
. The most worrying side-effect is the risk of secondary 
malignancies, which increases with higher cumulative doses of 
131
I 
43,53,54
. 
Levothyroxine treatment 
Patients with thyroid cancer operated with total thyroidectomy are dependent on life-long 
levothyroxine treatment. According to international recommendations, levothyroxine is given 
in doses both to replace the absent production of thyroid hormones and to suppress TSH 
32,33
. 
DTC cells express TSH-receptors and TSH is considered to be a growth factor in DTC 
55,56
. 
Suppression of TSH is associated with a decreased tumour recurrence, but the effect of 
suppression is seen only in patients with a higher risk of recurrence 
37,57,58
. On the other hand, 
subclinical hyperthyroidism is associated with side-effects. The most harmful complications 
are the increased risk of atrial fibrillation 
59
 and cardiovascular death 
60
. Diminished bone 
density in women over 50 years of age is another negative consequence of TSH suppressive 
therapy 
61,62
. In low-risk patients, TSH suppression is maintained for a shorter period, but in 
patients with loco-regional recurrence or metastatic disease the suppressive treatment can be 
life-long 
32
. As in the use of RAI, the benefit of TSH-suppression has been discussed over the 
last few years, and a more selective use in low-risk patients is advocated 
32,63
. The level of 
TSH-suppression is divided into three groups:  moderate or complete suppression is defined 
as TSH <0.1 mU/L; mild suppression as TSH 0.1-<0.5 mU/L (0.5 represents the lower limit 
of the reference range for TSH, which can be 0.3-0.5 depending of method); and no 
suppression as TSH ≥0.5 mU/L 32. In our studies, the lower limit is defined as 0.4 mU/L, 
according to the most wildly used method. 
2.3.7 Follow-up and treatment of recurrence 
DTC has a good prognosis with a 10-year overall survival of >90 % 
36
. Still, the recurrence 
risk is considerable which makes long-term follow-up necessary 
38
. The follow-up depends 
on recurrence risk and includes ultrasonography 
64
, evaluation of the levothyroxine dose, Tg 
measurement and WBS 
32
. WBS requires elevation of TSH levels either with THW or 
rhTSH. Measurement of Tg during the elevation of TSH makes the measurement more 
reliable 
32
.  
In loco-regional recurrent disease, surgery is the recommended treatment 
1
. In metastatic 
disease, radioiodine is the preferred first-line treatment, and can be repeated as long as the 
tumours are radioiodine avid 
32,65-67
. In radioiodine-avid disease, survival is significantly 
longer than in non-avid 
68
. External radiotherapy should be considered in gross residual 
cervical disease and in painful bone metastases 
6
. In progressive disease TSH suppression is 
of great importance for survival 
69,70
. Over the last few years, two tyrosine kinase inhibitors 
have been approved for locally advanced or metastatic DTC. Sorafenib 
71
 and lenvatinib 
72
 
have both showed improved progression-free survival and these drugs have substantially 
changed the treatment for patients with metastatic disease 
73
. 
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2.4 HEALTH-RELATED QUALITY OF LIFE 
Quality of life (QoL) is a broad multidimensional concept that includes individuals’ 
subjective perceptions of their position in life and evaluation of both the positive and negative 
aspects of life 
74
. Thus, it includes physical, functional, emotional and social well-being 
75
. 
Health, in itself, is one important domain in the overall quality of life 
74
. Subjectivity refers to 
the fact that QoL can be understood only from the patients themselves, and can be only 
assessed by them 
75
. To understand what health is, the constitution of the World Health 
Organization defined health in 1948 as follows: “Health is a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity” 76. To 
distinguish QoL in a more general sense from aspects important for clinical medicine and 
clinical trials, health-related quality of life (HRQoL) is used. HRQoL encompasses those 
aspects of QoL that are affected by disease or treatment of disease 
77
, symptoms and 
functions affected by the disease, and also the side-effects of treatment. The definition of 
HRQoL is not well defined, but it is generally agreed that “HRQOL is the functional effect of 
a medical condition and/or its consequent therapy up on the patient” 78. Thus it is subjective 
and multi-dimensional covering dimensions such as physical, psychological, occupational 
and social functioning” 77.  
Patient-reported outcomes 
The assessment of HRQOL does not usually include aspects such as needs assessment or 
satisfaction with care. A more inclusive term, patient-reported outcomes (PROs), includes 
any information about the status of a patient’s health condition 79, reported directly by the 
patient, without a proxy such as healthcare professionals or family members. A PRO can be 
measured by self-report or by interview, as long as only the patient’s views are documented 
80,81
. Thus, HRQoL is one type of PRO 
82. The use of electronic PROs is on the rise in today’s 
clinical trials. The process of obtaining PRO data is sometimes referred to as PRO 
measurement (PROM), and is increasingly used synonymous with PRO. PROs are gradually 
more used in clinical trials, and are mandatory in trials investigating new treatments in 
oncology. The use of PROM could help transform healthcare, while it not only helps patients 
and clinicians to make better decisions, it can also facilitate comparisons between healthcare 
providers and, in the end, stimulate improvements in healthcare 
83
. 
2.4.1 HRQoL as a conceptual model 
To better understand the concept of HRQoL and its determinants, Wilson and Cleary 
constructed a conceptual model that integrates the biological and psychological aspects of 
health and how they affect HRQoL 
84
. This model is the most frequently used to characterise 
HRQoL conceptually and was later revised by Ferrans and colleagues 
85
. The model of 
Ferrans has been assessed to be the most useful one, while the addition of the relationship 
between the individual characteristics and biological function was added 
86
. The model links 
traditional clinical variables with HRQoL and emphasises that HRQoL is more than just 
physical health. Additionally, it integrates both the biological and psychological aspects of 
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health outcomes. The model focuses on five different levels of patient outcomes. The first 
level is the biological function, which includes cellular and whole organ functions. The next 
level, symptoms, includes emotional, cognitive and physical symptoms. The functional status 
in this model focuses on the optimisation of the patient’s function that remains, and includes 
physical, social, physiological and cognitive functioning. The general health perception is a 
subjective evaluation that integrates all the components that come earlier in the model, thus 
this is a synthesis of all the different aspects of health. Overall quality of life, the last 
component of this model, is subjective well-being, and includes how happy or satisfied a 
patient is with his or her whole life. Although the simplified model has shortcomings, as 
individual perception of QoL is a complex phenomenon, the model still highlights important 
components 
85
. 
2.4.2 Why HRQoL is important to measure 
The ultimate goal of healthcare is not only to increase survival, but also to prevent further 
morbidity and to make patients feel better 
78,87
. Thus the rationale for measuring HRQoL is to 
clarify to which degree the medical condition, or its treatment, impacts the patients’ lives. 
HRQoL is an important measure along with other clinical measurements such as survival or 
tumour response to understand how patients experience a disease or its treatments. The 
measurements can then be used to study HRQoL changes over time or to compare HRQoL in 
patients with different diseases. Data from PROs, including HRQoL data from randomised 
clinical trials (RCT), can be used in clinical decision making, approval of new drugs, health 
policy, and also in reimbursement decisions 
88
. Evaluation of PRO data is now regarded as 
standard in clinical trials 
89
. 
Measuring HRQoL can benefit both patients and clinicians in two ways. Firstly, the use of 
HRQoL instruments in clinical trials can provide important evidence for how different 
treatments affect the patients, both which side-effects can occur and how the treatment affects 
HRQoL. This information is equally important for both patients and clinicians, and can help 
them to decide which treatment is the most suitable. Secondly, patients completing HRQoL 
questionnaires during treatment or follow-up provide information to the clinicians about their 
function, symptoms of the disease and possible side-effects from treatment. Thus, clinicians 
are informed about side-effects or other problems which are possible to treat and, in the end, 
this might improve the patients’ outcomes 87. In oncology, survival was the crucial end-point 
at the beginning, but with the introduction of more treatment options, HRQoL has risen to be 
an important part in the treatment decision making process 
90
. This seems to be even more 
important in an elderly cancer population, where older patients, compared with younger ones, 
tend to regard HRQoL as more important than longer survival 
91
.  
Measuring HRQoL in cancer patients is important, where patients have many symptoms and 
the loss of different functions.  Many of the symptoms and functions are not possible to 
measure with laboratory tests or imaging and it is important to rely on the patients’ 
descriptions. Moreover, several studies have found associations between HRQoL and 
survival 
92-94
, and HRQoL can even be a better prognostic marker than functional status 
95
. In 
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palliative care, the intent of treatments is mostly to improve HRQoL, not to prolong life, and 
thus measuring HRQoL is crucial 
96
. 
2.4.3 Response shift 
When measuring HRQoL over time, it might be difficult to know what the data should be 
compared to, and how the results should be interpreted. Patients experiencing a serious illness 
or deterioration of their functional status adapt themselves to their new condition and define 
new internal standards and values for their health after a period of time. Such subjective 
changes in the patients’ perceptions and self-evaluation of HRQoL are regarded as a response 
shift 
97
. Thus, patients might give different answers to HRQoL measurements over time, not 
only because their health or HRQoL has changed, but also because they have changed their 
own meaning of what health or HRQoL is to them. The patients may get used to various 
symptoms and a decrease of functions and, therefore, report diminishing levels over time. A 
change in HRQoL might reflect a response shift, an effect of the given treatment or a 
combination of both, which makes interpretation of HRQoL data challenging 
98
. 
2.4.4 Instruments for measuring HRQoL 
HRQoL can be measured through interviews, focus groups or questionnaires. Instruments 
used to measure HRQoL are either general, disease-specific, or detailed to measure a specific 
aspect of HRQoL and should preferably be completed by the patients themselves 
77
. 
 Generic instruments are intended for general use, irrespective of the illness or 
condition of the patients. They may often be applicable to healthy people. Examples 
are the Short-Form 36-Item Health Survey (SF-36) and Sickness Impact Profile (SIP). 
Advantages of generic instruments are that scores from patients with various diseases 
can be compared against each other and against the general population.  On the other 
hand, they fail to capture particular concerns or symptoms in patients with disease and 
lack the sensitivity to detect differences important to measure in clinical trials 
comparing different treatments.   
 Disease-specific instruments focus on disease-specific issues and examples are the 
European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 
and Functional Assessment of Cancer Therapy - General (FACT-G). These 
instruments measure functions and symptoms important in a specific disease but lack 
the possibility to explore particular issues in greater depth, and can therefore be 
combined with aspect-specific instruments.  
 Aspect-specific instruments are used to explore particular issues in greater depth. 
Examples are the Hospital Anxiety and Depression Scale (HADS) 
99
 and 
Multidimensional Fatigue Inventory (MFI). These instruments evaluate specific 
aspects of HRQoL and should normally be used together with a more general 
questionnaire. 
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2.4.5 Choosing an instrument 
When choosing a HRQoL instrument, it is important to take the aim of the trial into account. 
Disease-specific questionnaires have better sensitivity and/or specificity than generic ones 
regarding disease- and treatment-related issues. On the other hand, if the intention is to 
compare HRQoL in different diseases or to make health-economic assessments, generic 
questionnaires are preferred. If a disease-specific instrument does not have a generic question, 
it can be combined with a generic questionnaire. The same is applicable for instruments for 
specific aspects of HRQoL 
77
. In addition, other aspects to take into account are the timing, to 
use a wording understandable for all the included patients 
100
, to take into account missing 
values and to choose well-validated instruments. In clinical trials at least three time points are 
recommended, with the first one before the beginning of treatment. 
Instruments used to measure HRQoL should be well documented, the development needs to 
be described and the instrument should be validated and have good psychometric properties. 
Also, validated questionnaires can be troublesome when instruments tested in one context 
might not be valid in another, thus, the questionnaire should be suitable to the target 
population. In addition, the wording of the instrument is important and the scoring procedure 
needs to be defined. If the instrument does not cover all the issues important in the study, 
supplementary questions could be added at the end of the validated questionnaire. 
Psychometric properties have four important independent basic fundaments, which are 
interrelated 
77
: 
 Validity – does the instrument measure what it is intended to and is it useful for the 
intended purpose? In HRQoL assessment, does the instrument really measure 
HRQoL? Content validity relates to the adequacy of the content of an instrument in 
terms of the number and scope of the individual questions, are all aspects covered and 
are the included questions relevant? Criterion validity involves assessing the 
instrument against the true value, or against another accepted standard, and by 
comparing it against other established instruments. Construct validity evaluates  
whether an instrument measures the construct it was designed for. Thus, all the items 
of a subscale should relate to a single latent variable and items from one subscale 
should not correlate with other latent variables. 
 Reliability – determines that the instrument produce reproducible and consistent 
results when circumstances remain the same. Reliability is used for both internal 
reliability and repeatability. Internal reliability assesses the homogenity of multi-
item scales, that is, all items on a domain should measure the same thing. Thus, it is a 
form of validity. Repeatability is another measure of reliability, that is, the stability 
of measurements. If the instrument is used several times on the same patient, and the 
patients’s condition has not changed, then the result should be the same.    
 Sensitivity – is the ability of the instrument to detect differences between groups, e.g. 
patients with mild disease from those with more severe disease or between two 
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treatment groups. The more sensitive the instrument is the smaller sample size is 
needed. This can be assessed in cross-sectional studies.  
 Responsiveness – is the ability of the instrument to detect changes within patients, if 
the patient’s health status changes over time. This can be assessed longitudinally in 
patients in whom change is expected to occur. 
Sensitivity and responsiveness can be reduced if floor or ceiling effects are present, which is 
if a high proportion of the patients grade themselves as having the minimum or maximum 
scores, respectively 
77
. 
2.4.6 Short-Form 36-item Health Survey 
The Short-Form 36-Item Health Survey (SF-36) is a HRQoL instrument developed by Ware 
et al. to evaluate general health status and to fill a gap between lengthy questionnaires used in 
research and coarse single-item questionnaires. It is designed to assess general health, and is 
not specific to any age, disease or treatment group. The SF-36 was mainly developed based 
on various earlier instruments measuring limitations in physical, social and role functioning, 
mental health and general health perceptions, and two additional concepts supported by 
empirical studies, bodily pain and vitality 
101
. It has become the most widely used of the 
general health status measures 
102,103
. 
SF-36 is a multidimensional instrument with 36 questions measuring eight health profiles: 
physical functioning (PF, ten items), physical role functioning (RP, four items), emotional 
role functioning (RE, three items), social functioning (SF, two items), bodily pain (BP, two 
items), mental health (MH, five items), vitality (VT, four items) and general health (GH, five 
items). In addition, there is a general health transition question: “Compared to one year ago, 
how would you rate your general health now?”. This question, however, is not included in the 
final score 
101
. The health profiles can be combined into two summary measures; the physical 
component summary (PCS) and the mental component summary (MCS). The physical 
component summary is most correlated with PF, RP and BP whereas MH, RE and SF 
contributes most to the mental component summary. Three of the scales; VT, GH and SF 
have noteworthy correlations with both components 
104
.  
The International Quality of Life Assessment (IQOLA) Project was established in 1991 to 
translate the SF-36 into a range of languages and to validate, norm, and document the 
translations. SF-36 has been translated into Swedish, and it has been psychometrically tested 
and validated in a Swedish normative population 
105-108
. A Swedish manual and interpretation 
guide is available, with data from the Swedish general population collected 1991-1992 
109
. 
Data from a Swedish general population is also available from 2002 
110
. 
2.4.7 Psychometric properties of SF-36 
Several studies have investigated the psychometric properties of SF-36. SF-36 was developed 
using items from previous questionnaires and many of the items have been widely used and 
tested in earlier studies, thus the content validity is assessed as good. Additionally, when SF-
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36 has been compared to other widely used generic health instruments, the criterion validity 
has been evaluated as good 
104
. Construct validity measured with convergent and discriminant 
validity has been tested and shown to be good for all items. Reliability has been evaluated 
using internal consistency and test-retest. Internal reliability, measured with Cronbach α, has 
been shown to exceed the recommendations on a group level 
111
. Sensitivity in SF-36 has 
been shown to discriminate between diseases of different severity, and also to distinguish 
psychiatric disease from medical conditions in a Swedish population 
106
. In addition, SF-36 
has been shown to be sensitive measuring HRQoL in thyroid cancer 
45,47,112
. Responsiveness 
has been shown as change in health status over time in four common clinical conditions; low 
back pain, menorrhagia, suspect peptic ulcer and varicose veins and also in the postoperative 
period after colorectal surgery 
113,114
. SF-36, version 2, is thought to have better 
responsiveness due to changes in the response formats of the role functioning scales because 
of improved precision, reliability and validity 
108
. 
2.4.8 Interpreting results from SF-36 
The SF-36 items and scales are constructed for scoring using the Likert method of summated 
ratings 
115
. The scores from each domain are transformed into a scale ranging from 0 to100 
where 100 indicate the best possible health. Statistical significance is not the only criterion 
used to compare data in HRQoL, because it can be reached although there is no clinical 
relevance for the patients. Statistical significance is important to assure that the results are not 
explained by chance fluctuations alone, but significance can be found in a large sample 
without having any clinical meaning for the patients 
77
. To evaluate if differences between 
groups or between different measurement points in one patient are relevant, the differences 
should also be clinically significant. The smallest difference that is significant for patients is 
often called minimally important difference (MID). The MID is deﬁned as the smallest 
difference in score which patients perceive as beneﬁcial or negative 116,117.  Different methods 
to evaluate MID exist. In anchor-based methods, HRQoL changes are compared with clinical 
changes or results. Osoba suggested that a difference of 5-10 points between groups on a 100-
point scale is interpreted as a clinically small relevant MID, 10-20 points is interpreted as a 
moderate difference and over 20 points is a large difference 
118
. In distribution-based 
approaches, comparisons are based on a statistical distribution of results. As presented by 
Cohen, a standard deviation (SD) between groups of at least 0.2 is interpreted as a small 
difference, 0.5 as a moderate, and 0.8 as a large difference 
119
. A more conservative estimate 
is that the effect size of a 0.5 SD is likely to be clinically meaningful 
120
. 
2.4.9 The rationale for choosing instruments 
At the beginning of this thesis there were no validated disease-specific questionnaires 
regarding thyroid cancer in Swedish. As the treatment of thyroid cancer does not include the 
major cancer treatments, such as chemotherapy and external radiotherapy, the cancer-specific 
questionnaires like as EORTC-QLQ C30 or FACT-G were not regarded as suitable for this 
patient population. Thus, a generic questionnaire was regarded as appropriate. SF-36 is the 
most widely used generic instrument, there is a validated Swedish translation and data from 
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Swedish general populations are available for comparisons. In addition, is has been regarded 
as sensitive in thyroid cancer. As a complement, a study-specific questionnaire was 
developed to capture symptoms important to patients with thyroid cancer (see Appendix).  
2.4.10 The study-specific questionnaire 
The study-specific questionnaire includes important sociodemographic questions about level 
of education, work, civil status, smoking, weight changes, and menopause status. In addition, 
comorbidities, thyroid cancer treatment and recurrences are asked for. To study thyroid 
cancer related symptoms and side-effects from treatment these issues are extensively asked 
for. The last questions include aspects about change in view of life, fear of recurrence and, in 
addition, open-ended questions about the same aspects, as open-ended questions have been 
shown to reveal additional information 
121
. 
The study-specific questionnaire was developed by the research group, which included 
knowledge about both the surgical and oncological treatment of thyroid cancer and, in 
addition, expertise in measuring HRQoL. The questions regarding symptoms and side-effects 
from thyroid cancer were based on literature review and clinical experience. The 
questionnaire was pilot-tested in five patients with thyroid cancer and no changes were made. 
The patients regarded the questions to be easy to understand and answer, and also not 
offensive. 
2.5 FEAR OF RECURRENCE AND ANXIETY 
Anxiety and fear of recurrence are both well-known factors affecting quality of life in cancer 
patients. The number of cancer survivors is increasing worldwide 
13,17
, and this emphasises 
the importance of exploring factors affecting their quality of life.  
2.5.1 Fear of recurrence 
Fear of recurrence affects 39-97% of all cancer patients and 22-87% reported moderate to 
high levels 
122,123
. In the majority of the studies, fear of recurrence is stable over time 
122
. It is 
one of the most commonly reported issues bothering cancer patients and one of the most 
distressing consequences 
124
. With an increasing number of long-term cancer survivors this 
fear becomes an important factor affecting their lives. This very term is defined as fear of 
recurrence of the disease, disease progression, or dissemination of the disease 
122,125
. 
Recently, a novel definition has been introduced: “Fear, worry, or concern relating to the 
possibility that cancer will come back or progress” 126. Fear of recurrence should be 
differentiated from the psychiatric concept of anxiety, as cancer patients have a real threat 
and their reactions should be considered as a normal and a rational response to the life 
threatening disease 
125
. If the fear of recurrence develops to a dysfunctional state, i.e. 
affecting quality of life and social functioning, treatment should be offered. Thus, it is 
important to identify patients at a greater risk of developing a fear of recurrence and offer 
them interventions.  
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Determinants of fear of recurrence 
A demographic factor associated with fear of recurrence is age, as young age in general, and 
young age at diagnosis is an important predictor of fear of recurrence 
127,128
. Sex, education 
and marital status do not have a clear correlation with fear of recurrence 
125,127
, whereas 
having children seems to be related to higher levels of fear 
129
. Among disease- and 
treatment-related factors, time from diagnosis shows no association with fear of recurrence 
125
 
and progression of the disease shows conflicting results 
122,130
.  
Several psychological factors are associated with an increased fear of recurrence such as 
neuroticism 
131
, anxiety, depression 
125
 and lower optimism 
132
. Coping strategies play a role 
in decreasing the fear of recurrence. Physical symptoms such as fatigue and pain are 
associated with fear of recurrence whereas comorbidities show no associations. Strong 
evidence emerged for negative associations between QoL and fear of recurrence. Cancer 
survivors with a fear of recurrence express lower QoL both on physical and mental domains 
122,133
. A surprising finding is that levels of fear of recurrence seem to be comparable between 
different cancer diagnoses 
134
. As a conclusion, patient-related characteristics seem to be 
more important predicting fear of recurrence than treatment- and tumour-related factors 
135
.  
Measuring fear of recurrence 
Fear of recurrence has been investigated in numerous studies, and the assessment has been 
carried out with longer (>10 items) and shorter (2-10 items) questionnaires. In addition, 
subscales within quality of life questionnaires and single items have been used. The most 
used questionnaires are the Fear of Progression Questionnaire and the Cancer-Related Health 
Worries Scale 
122,123
. As there is no consensus about which levels of fear of recurrence are 
clinically important, the interpretation of results is challenging 
122
. Both group interventions 
and face-to-face interventions have an effect on fear of recurrence in cancer patients 
136,137
. 
2.5.2 Anxiety 
To receive a cancer diagnosis is traumatic and can be perceived as a threat to patients’ lives. 
According to Cullberg, a crisis reaction can be divided into four different stages; shock, 
reaction, process/adaptation, and reorientation. The first two stages represent the acute crisis 
while the two latter ones constitute the adaptation process. When the crisis reaction 
progresses according to the four stages, it will lead to better recovery. However, several 
factors can disrupt the process and impair recovery 
138
. 
Coping mechanisms play a major role in handling difficult life events, primarily to avoid 
anxiety. The process of coping is initiated only if important values are threatened or lost and 
the meaning and intent of coping is to handle demanding situations. The coping process 
consists both of understanding the situation and of what can be done or how someone can 
protect themselves 
139
. If the crisis after a cancer diagnosis is not processed and coping 
mechanisms fail, anxiety is a possible outcome.  
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Anxiety is known to be common in cancer survivors and is the most prevalent of mental 
disorders 
140
. Anxiety has a prevalence of 18% in one meta-analysis 
141
 and 11.6% in patients 
with various cancer diagnoses and disease stages 
140
. It seems to be more common in patients 
with breast, head and neck cancer and melanoma 
140
, and high levels of anxiety are seen in 
both cured patients and in those with progressive disease 
141-143
. Variations of anxiety are seen 
over time 
144
 and the highest prevalence is shown soon after diagnosis 
145
. Moreover, the risk 
of anxiety during follow-up seems to be increased in patients with pre-existing anxiety and in 
those with high levels of anxiety around diagnosis 
146
. It is also correlated to a fear of 
recurrence 
122,147
. 
2.6 QUALITATIVE RESEARCH METHODS 
When using quantitative questionnaires, reliability and sensibility are usually good due to the 
psychometric testing of the questionnaires. In addition, validity might be strong but a draw-
back is that the respondents are only allowed to answer predefined questions. Important 
questions not covered by the questionnaire might be of high relevance, and therefore missed. 
To explore new, and partly unknown, knowledge of phenomena connected to the human 
experience, such as expectations, thoughts and attitudes, a qualitative study method is suitable 
148
. Moreover, questionnaires do not allow for personalised follow-up questions. For this 
reason, qualitative methods constitute an important complement to quantitative measurements 
in order to explore a phenomenon in depth 
149
. Qualitative data can be gathered by different 
kinds of collection methods; e.g. interviews or focus groups, observational studies or written 
documents 
148
. 
2.6.1 Qualitative interviews 
Interviews are the most used qualitative techniques in healthcare, and both semi-structured 
and in-depth interviews are useful in gathering data. In semi-structured interviews an 
interview guide with open-ended questions can be used 
150
 to encourage spontaneous 
comments. To validate and deepen the information, follow-up questions are important 
148,150,151
. In-depth interviews are less structured, and may cover only a few issues, but in 
greater detail. When conducting interviews, it is important to explore what patients are saying 
in as much detail as possible, and try to find new unknown areas of information 
152
. Good 
interview questions should be open-ended, neutral, sensitive, and easy to understand for the 
interviewee 
148
. The audio-recording of interviews instead of taking notes is regarded as a 
suitable method, in order not to miss any details or to interfere with the process of 
interviewing. It is followed by a verbatim transcription of the recordings 
152
. 
2.6.2 Sampling 
Sampling in qualitative research differs from quantitative research. In contrast to large 
random samples allowing for the calculation of probabilities in quantitative research, 
purposeful sampling is the preferred method in qualitative studies 
153
. Purposeful sampling 
covers various sampling methods and all have in common the intent to select information-
rich cases for in-depth studies. Examples of purposeful sampling are single significant cases 
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sampling (to gather deep understanding of the subject), comparison focused sampling (where 
cases are selected to compare and contrast them), and group characteristic sampling (selecting 
cases to create an information-rich group). One important example of group characteristic 
sampling is the maximum variation sampling, in which cases are picked purposefully with a 
wide range of characteristics to document diversity and to identify important common 
patterns 
148
. In contrast to quantitative research, the number of patients is significantly lower 
and not always predefined. Saturation is the term (initially defined in Grounded theory) used 
when no new information is provided from, for example, interviews, and the data gathering 
process can be terminated 
154,155
. 
2.6.3 Analysing qualitative data 
When analysing qualitative data, different methods can be used. Qualitative content analysis 
is a method used to interpret meaning from the content of text data by systematically 
classifying data with different codes and, thus, identifying common themes 
150
. Several steps 
are required in the analyses differing between the methods, and usually include the following 
steps: reading of the text to get a picture of the data, preliminary coding of meaning bearing 
units (sentences containing aspects related to the research question) in the text and 
comparison of codes and gathering codes into categories (a group of contents that has 
something in common). Developing themes is the last part of the analysis, meaning a thread 
of an underlying meaning that can be found between condensed meaning units, codes and 
categories 
150,156,157
. Inductive analysis is defined as discovering patterns, themes and 
categories from the research data. On the other hand, in deductive or abductive analysis, data 
are analysed in agreement with a pre-existing framework 
148
. In addition, the terms latent and 
manifest are important when analysing qualitative data. Latent refers to analysis of the 
interpretation of the underlying meaning of the data, whereas a manifest analysis refers to 
what the text says and the obvious components of the data 
156
. 
2.6.4 Trustworthiness 
The concepts of describing trustworthiness differ between qualitative and quantitative 
research. Trustworthiness can be defined in several ways and useful concepts are credibility, 
dependability, and transferability according to Graneheim et al 
156,158
. Credibility refers to 
the confidence in how well findings and the data analysis suit the focus of the study. The 
sampling method is crucial in achieving credibility and, as discussed earlier, purposeful 
sampling is preferred. To gather enough data for the purpose of the study the number of 
participants is not fixed, which is in contrast to quantitative research. Instead, saturation is 
paramount, as the amount and quality of the data depends on the aims of the study, that is 
how broad or limited the predefined phenomenon we intend to study is. In addition, it is 
important to demonstrate differences and similarities between categories, and showing 
representative quotations is one approach. Dependability, another aspect of trustworthiness, 
refers to the creation of categories. To decide which codes should be included in which 
categories is a matter of dependability and to include several researches in the analysis is one 
way of addressing it. Transferability refers to the degree of which results can be transferred 
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to other contexts. By giving a clear description of the context, selection of participants, data 
gathering and analysis, transferability can easier be judged by the reader 
156,158
. 
2.7 HEALTH-RELATED QUALITY OF LIFE IN THYROID CANCER 
Due to the good prognosis of thyroid cancer long-term survival is excellent. Despite the 
longevity of the disease, the risk of recurrence remains considerable for decades and long-
term follow-up is needed. Thus, survival is not, alone, sufficient as an outcome measure and 
HRQoL has risen to be an important factor in DTC. 
According to a review, HRQoL in DTC has been investigated in a number of studies with 
results showing both lower and similar HRQoL compared with a general population 
159
. 
HRQoL can be affected at different time points during the disease trajectory, from diagnosis, 
surgery, radioiodine treatment to follow-up and possible recurrence. The effects of surgery, 
levothyroxine withdrawal and, to a lesser extent, follow-up have been studied according to 
HRQoL. On the other hand, HRQoL has been scarcely studied at the time of diagnosis, in 
prospective studies, or in patients with recurrent disease. 
2.7.1 HRQoL related to surgery and radioiodine treatment 
Surgery 
Several studies focus on HRQoL related to surgery. HRQoL is studied pre-operatively and 
followed up at three, six and twelve months in patients having thyroid surgery for either 
benign or malignant thyroid diseases. HRQoL is lower compared with the general population 
during the first six months with a trend of recovery during follow-up. No difference is seen 
between hemithyroidectomy and total thyroidectomy, and no difference is seen between 
patients with benign or malignant thyroid disease 
160
. In thyroid cancer with tracheal invasion, 
tracheal resection gives considerable per-operative symptoms. One year after surgery these 
patients have even better HRQoL than the patients treated with surgery for oropharyngeal 
cancers. All these patients would have chosen the same treatment modality again 
161
. Patients 
treated with modified radical neck-dissection are shown to have worse chewing function and 
more shoulder problems compared with patients treated with thyroidectomy with or without 
central lymph node dissection 
162
. Different surgical methods are compared, and robotic 
thyroidectomy seems to give less sensory changes and better cosmetic outcome, whereas the 
other QOL measurements seem equal 
163,164
. 
Radioiodine treatment 
The THW used for radioiodine treatment, WBS and Tg measurement has a clearly 
demonstrated negative effect on HRQoL. In several randomised trials, THW is compared 
with rhTSH during post-operative radioiodine treatment. In all studies, patients in the THW 
group have a significantly lower HRQoL compared with the rhTSH group 
45-47,165-167
, but no 
remaining differences are seen after six months 
47
. In addition, similar impairments of 
HRQoL are shown when comparing THW and rhTSH during follow-up investigations with 
 20 
 
WBS, and HRQoL during THW is even worse than in patients with congestive heart failure, 
depression and migraine 
112
. Of those patients having both THW and rhTSH on separate 
occasions, 127 of 128 patients would have chosen rhTSH in the future 
168
. The symptoms 
patients mostly mention during THW are fatigue, intolerance to cold, sleep changes and 
weight gain 
169
.  
Radioiodine doses higher than 5.5 GBq are associated with significantly worse pain, 
swallowing, chewing, taste, and anxiety scores 
162
, and in addition, sialoadenitis is more 
frequent 
170
. 
2.7.2 HRQoL in thyroid cancer survivors 
Several studies focus on HRQoL in thyroid cancer survivors during follow-up. The majority 
of the studies demonstrate lower HRQoL in thyroid cancer survivors compared with a general 
population 
171-174
, although two studies show no significant differences 
175,176
. Examples of 
domains with lower scores compared with the general population are physical, role, 
emotional, cognitive and social functioning 
173
. HRQoL in thyroid cancer is also compared 
with HRQoL in patients with breast cancer, colon cancer, gynaecological cancer and glioma. 
Although survival is significantly lower in those cancer diseases, HRQoL is at the same level 
177
.  
A few studies assess HRQoL longitudinally. Although HRQoL increases over time, it does 
not reach the same levels as a general population 
171
. During the first years of follow-up, 
HRQoL seems to fluctuate and starts increasing after five years 
178
. In one study, HRQoL is 
measured both preoperatively and during two years of follow-up. Although HRQoL increases 
during follow-up, it does not reach the same level as the general population 
179
. In another 
study HRQoL is measured pre-operatively and during a one-year follow-up, and according to 
these results HRQoL return to baseline values 
180
. One study demonstrates that HRQoL 
measured at diagnosis seems to predict HRQoL at follow-up 
181
. 
Thyroid-stimulating hormone 
TSH suppressive therapy is thought to affect HRQoL negatively 
182
, but the results are not 
consistent. Two studies shows no effect of high TSH levels and HRQoL during follow-up 
183,184
, and one additional study investigates several thyroid function tests without finding any 
associations with HRQoL 
185
. On the other hand, in another paper, DTC patients with 
subclinical hyperthyroidism are compared with euthyroid, non-cancer patients. HRQoL is 
lower in DTC patients measured with SF-36, fatigue is higher and muscle function in the 
upper limbs is reduced 
186
. In the same cohort, patients are randomised to an exercise 
programme or a control group. After three months, patients in the exercise group show an 
increased HRQoL on five of eight SF-36 domains 
187
. 
Fatigue is one of the most commonly perceived symptoms reported by thyroid cancer 
patients, and negatively affects HRQoL 
173
. Compared with a general population, thyroid 
cancer patients have significantly higher levels of fatigue 
188
 and they have similar levels of 
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fatigue compared with other cancer patients 
189
. Those patients that are more physically active 
are shown to have lower levels of fatigue 
190
, and exercise contributes to better HRQoL in 
thyroid cancer patients 
191
. Other frequent symptoms negatively affecting HRQoL are 
sleeping problems 
192
, irritability, and nervousness 
172,173,193
, which all negatively affect 
HRQoL.     
Few patient characteristics seem to be associated with HRQoL in thyroid cancer. Lower age 
shows conflicting results, and is both associated with lower 
178,194
 and higher HRQoL 
162,174
. 
Lower HRQoL in women could be expected, but this is scarcely shown 
178
. In addition, lower 
education is associated with lower HRQoL 
174,178
. 
2.7.3 Fear of recurrence and anxiety in thyroid cancer 
Fear of recurrence is frequently present in thyroid cancer. Surprisingly, it is as common in 
thyroid cancer as in other cancer diagnoses with a worse prognosis 
134
. About 35% of thyroid 
cancer patients have some kind of fear of recurrence 
195
 and, additionally, one in seven 
experiences a lot of fear 
196
. Fear of cancer recurrence is also the most often mentioned worry 
in a phase I study developing an EORTC module for measuring HRQoL in thyroid cancer 
197
. 
Anxiety varies among different cancer diagnoses, but is surprisingly high in thyroid cancer 
patients compared with patients with more aggressive tumours 
144
. Anxiety seems to be one 
important determinant of HRQoL 
198
, and between 17-25% of thyroid cancer patients have 
significant anxiety 
193,196,199
. Psychological and behavioural interventions during the first year 
after RAI treatment show declining levels of anxiety and depression 
200
. 
2.7.4 HRQoL evaluated with qualitative methods 
HRQoL in DTC patients is described in a few qualitative studies. The most prominent finding 
is the “good cancer” definition. The experience of having a “good cancer” is a paradox. On 
one hand, patients are glad to have a disease with a good prognosis. On the other hand, the 
optimism invalidates their fears of having a cancer and they feel dismissed by the healthcare 
system by not being offered psychosocial support 
201-203
. In addition, they feel isolated from 
other cancer patients, as the physical signs and symptoms differ from the others 
204
. 
The impact of DTC is described on both emotional and cognitive functions across all 
treatment phases. Patients with recurrent or metastatic disease are most affected according to 
daily activities, mobility, and energy levels 
204
. Patients with loco-regional recurrence have 
significant psychological distress and worry about further recurrence, however, they also 
appreciate life more and evaluate family relationships higher 
205
. 
In addition, receiving a cancer diagnosis is life-changing, resulting in uncertainty for the 
future and a fear of recurrence. Several participants express the need for long-term support 
during follow-up 
203
, and the need for adequate information about treatment and follow-up 
routines is evident 
206
. Follow-up of patients with thyroid cancer is crucial both due to the 
life-long levothyroxine treatment and the remaining recurrence risk decades after the 
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diagnosis. Follow-up options are studied with open ended questions, and the important factor 
for patients is the reassurance that the method of follow-up, whether it is primary care or 
specialised care, provides adequate care 
207
. 
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3 AIMS 
The overall aim of this thesis was to study aspects of quality of life in patients with DTC, and 
to identify factors affecting quality of life from diagnosis and during follow-up. 
The specific aims of Studies I-IV were: 
I) To study long-term health-related quality of life in patients with DTC compared with 
the general population in Sweden, more than 10 years after treatment for DTC.  
 
II) To study treatment related side-effects and their impact on health-related quality of 
life in patients with DTC, more than 10 years after treatment for DTC. 
 
III) To prospectively compare short-term health-related quality of life in DTC patients, 
between diagnosis and one-year of follow-up. 
 
IV) To broaden the understanding about anxiety and fear of recurrence in thyroid cancer 
patients through semi-structured interviews. 
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4 MATERIAL AND METHODS 
4.1 OVERVIEW 
An overview of the material and methods used in Studies I-IV included in this thesis is 
provided in Table 1. 
 
Table 1. Overview of material and methods in Studies I-IV 
 Study I Study II Study III Study IV 
Design Cross-sectional 
Population-based 
Cross-sectional 
Population-based 
Prospective 
Population-based 
Qualitative 
interview study 
Data source DTC diagnosis 
1995-1998   
Sweden 
DTC diagnosis 
1995-1998    
Sweden 
DTC diagnosis 
2012-2017   
Sweden 
DTC patients 
Stockholm  
Study time 14-17 years after 
diagnosis 
14-17 years after 
diagnosis 
At diagnosis and at 
1-year of follow-up  
3 months-18 
years after 
diagnosis 
Outcome Long-term HRQoL 
Anxiety             
Fear of recurrence 
Long-term HRQoL 
Comorbidities 
Thyroid symptoms 
Short-term HRQoL 
TSH             
Anxiety             
Fear of recurrence 
Patients’ 
experiences of 
DTC 
Quality of life 
measurements 
SF-36 and study- 
specific 
questionnaire 
SF-36 and study- 
specific 
questionnaire 
SF-36 and study- 
specific 
questionnaire 
Semi-structured  
interviews 
Methods of 
analyses 
Mann-Whitney    
U-test, Kruskal 
Wallis, one-sample 
t-test 
Mann-Whitney    
U-test, Kruskal 
Wallis, Multivariate 
logistic regression 
Mann-Whitney    
U-test, Kruskal 
Wallis, Wilcoxon 
signed-rank test, 
Multivariate 
logistic regression 
Qualitative 
content analysis 
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4.2 STUDY DESIGN  
Four studies are included in this thesis. Studies I and II are cross-sectional population-based 
studies evaluating HRQoL, fear of recurrence, and thyroid-related symptoms. Study III is a 
prospective population-based study assessing HRQoL, TSH-values, anxiety and fear of 
recurrence during follow-up. Study IV is an interview study using qualitative content analysis 
addressing anxiety and fear of recurrence. 
4.3 DATA SOURCES 
4.3.1 The Swedish Cancer Registry 
The Swedish Cancer Registry was established in 1958 and is held by the National Board of 
Health and Welfare. The registry is nationwide and population-based and is generally 
considered to be of good quality with a national coverage of 96.3% in 1998 of all diagnosed 
cancers in Sweden 
208
.  The purpose of the cancer registry is to monitor cancer incidence and 
its temporal trends in Sweden, and it aims to provide statistics both to the public and for 
research purposes. 
4.4 STUDY POPULATION  
4.4.1 Studies I and II 
For the purpose of Studies I and II, all DTC patients aged 35-64 years diagnosed between the 
years 1995-1998 in Sweden were identified from the Swedish Cancer Registry. The aim was 
to study long-term HRQoL 14-17 years after diagnosis. By choosing the age group of 35-64 
year-olds at inclusion in 2012, the patients were 18-50 years old at diagnosis. Younger 
patients would have been children at the time of diagnosis and older patients might have had 
heterogeneous confounding factors 
209
. Inclusion criteria were a diagnosis of DTC and having 
a permanent address in Sweden. 
4.4.2 Study III 
For the purpose of Study III, newly diagnosed DTC patients were included. Patients were 
prospectively included from January 2012 to March 2017. All hospitals in Sweden (n=13) 
treating DTC patients with radioactive iodine were invited to participate. All hospitals 
participated and, thus, the inclusion was population-based. Inclusion started at various time 
points in the different hospitals; therefore the inclusion was not evenly distributed 
geographically. Inclusion criteria were: age ≥18 years at diagnosis, Swedish speaking, a 
primary diagnosis of DTC, scheduled for a total thyroidectomy with or without lymph node 
dissection and planned for RAI treatment. Exclusion criteria were: small DTC (T1a), no 
planned RAI treatment, ongoing treatment for other malignancies, ATC or MTC and a 
recurrence of DTC. Patients were identified during the post-operative multi-disciplinary 
conference and included after surgery, but before RAI treatment. Patients were followed-up 
after one year. 
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4.4.3 Study IV 
For the purpose of Study IV, patients with DTC followed-up at the Department of Oncology 
at Karolinska University Hospital in Stockholm, Sweden, were invited to participate in an 
interview study. Karolinska University Hospital serves the entire county of Stockholm (2.2 
million inhabitants) with specialised care for thyroid cancer patients. Study participants were 
eligible if they were over 18 years of age and were fluent in Swedish, had a diagnosis of 
DTC, and were previously treated with minimum total thyroidectomy and RAI.  
The patients were selected through purposeful maximum variation sampling 
148
 regarding 
age, sex, stage of disease, education, and time since diagnosis. The number was determined 
based on “saturation”, that is when the collection of data ceases to provide substantial new 
information and when patterns in the data become evident. The patients were contacted by 
telephone, and were given the opportunity to reflect upon whether they would wish to 
participate when contacted again. During the telephone call, information about the study’s 
aims and procedures was provided. When the patient agreed to participate, an interview was 
booked at a time and place chosen by the interviewee. Interviews were conducted in patients’ 
homes, at the Karolinska University Hospital, in a patient’s office or at a café. During the 
interviews, saturation was achieved after 15 interviews. To accomplish saturation, inclusion 
was continued with six further patients to ensure that no new aspects would emerge, which 
was not the case. None of the patients declined to participate. Verbal informed consent was 
obtained both before and after the interviews. 
4.5 DATA COLLECTION 
4.5.1 Studies I and II 
Patients fulfilling the inclusion criteria were invited to participate by mail. By completing and 
returning HRQoL questionnaires, the patients consented to participate and agreed for their 
data to be used for research purposes. Up to two reminding letters were sent to non-
responders. All data used in the study were gathered from the questionnaires. SF-36 provided 
data on HRQoL whereas sociodemographic data, as well as comorbidities, thyroid-related 
symptoms, information about received cancer treatment and possible recurrences, fear of 
recurrence and view of life were gathered from the study-specific questionnaire. 
4.5.2 Study III 
In Study III, those patients fulfilling the inclusion criteria were invited by mail or received 
questionnaires during their first visit after the multi-disciplinary conference. By completing 
and returning the questionnaires, the patients consented to participate in the study and their 
data to be used for research purposes. Up to three letters were sent to non-responders. SF-36 
provided data on HRQoL and the study-specific questionnaire provided information about 
sociodemographic data, comorbidities, thyroid-related symptoms, fear of recurrence and view 
of life. Clinical data such as tumour characteristics, surgical and radioiodine treatment, 
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laboratory data, and information about possible recurrences were gathered manually by the 
first author through reviewing medical records. 
4.5.3 Study IV 
Data was gathered by semi-structured interviews that were audio-recorded and transcribed 
verbatim. The interview guide included questions regarding the experience of living with 
thyroid cancer. Examples of questions were: “Has something changed after your cancer 
diagnosis?”, “Has your view on life changed?”, and “How have you experienced your disease 
from diagnosis until today?”. When needed, follow-up questions were posed. The interviews 
were carried out by two interviewers, co-author IW conducted eight of the interviews and the 
first author conducted the others. The interviews lasted for 20-65 minutes. 
4.6 HRQOL MEASUREMENTS AND QUALITATIVE INTERVIEWS 
In Studies I-III two different HRQoL questionnaires were used: SF-36 and a study-specific 
questionnaire. In Study IV semi-structured interviews were used to explore the effect of DTC 
on the lives of the patients.  
4.6.1 SF-36 
SF-36 is a HRQoL questionnaire developed to measure general health, and can be used in 
different diseases. SF-36 is described in the Background. As there was  
Scoring and presentation 
The results from SF-36 were linearly transformed to a score between 0-100 according to the 
scoring manual 
109,210
. A high score represents a higher function or better quality of life. 
Clinical relevance was assessed on statistical significance but, in addition, a difference in 
scores >5 points was regarded as clinically relevant according to Osoba 
118
.  
In Study I, mean scores were compared to an age- and sex-matched Swedish general 
population. Differences in mean scores based on the number of comorbidities, that is “no”, 
“one” or “two or more” comorbidities, were measured. In addition, differences in mean 
scores were calculated based on fear of recurrence and recurrence and grouped into “no fear” 
“fear” and “actual recurrence” and change in view of life grouped into “no or positive” and 
“negative”. 
In Study II, SF-36 mean scores were compared between patients with thyroid-related 
symptoms grouped into “no” symptoms, “moderate” or “major” symptoms. In addition, 
different thyroid-related symptoms were grouped as above, and mean SF-36 scores were 
compared between patients with “no” and “major” symptoms and between “no” and 
“moderate and major” symptoms.  
In Studies II-III, SF-36 responses were dichotomised into ‘‘good’’ versus ‘‘poor’’. The cut-
off was based on clinical relevance. Patients answering “no” or “little” symptoms / impact on 
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HRQoL, for all questions on one domain, were categorised as having good HRQoL. 
Otherwise, they were categorised as having poor HRQoL. 
In Study III, SF-36 mean scores were compared according to levels of TSH suppression: 
“no”, “mild” and “moderate or complete”. SF-36 mean scores were also compared based on 
fear of recurrence grouped into “no”, “seldom” and “often” and change in view of life 
grouped into “no or positive” and “negative”. 
4.6.2 Study-specific questionnaire 
The study-specific questionnaire (see Appendix) includes questions concerning 
sociodemographic factors, comorbidities, received treatment, possible recurrences and, 
symptoms and side-effects possibly related to thyroid cancer. The term ‘‘thyroid-related 
symptoms’’ was used to cover both symptoms that probably are related to thyroid disease or 
levothyroxine treatment and side-effects from surgery and/or radioiodine treatment. The 
specified symptoms related to thyroid disease or levothyroxine treatment were: fatigue, 
sleeping disorders, irritability, lower stress resistance, muscle weakness, bodily restlessness, 
sweating, palpitations, and flushes. The following symptoms with a probable relation to 
thyroid cancer treatment were also registered: xerostomia, hoarseness, dysphagia, numbness 
in the operation area and, salivary gland problems. In addition, questions about fear of 
recurrence and change in view of life were included; both of a quantitative character and as 
open-ended questions.  
For analysis, comorbidities were divided into three groups: “no”, “one” and “two or more”. 
As regards symptoms related to thyroid disease or levothyroxine treatment, the patients 
completed a questionnaire with five verbal alternatives (Likert scale). The results were 
divided into three groups for the analysis: “no”, “moderate” (including “a little” and 
“moderate”), and “major” symptoms (including “quite a bit” and “very much”). Treatment-
related symptoms were also divided into “no”, “moderate” and “major” symptoms. 
In Studies I and II, treatment-related information was gathered from questionnaires and, in 
Study III tumour and treatment-related information was gathered from medical records. 
Missing data 
Missing data according to SF-36 in Studies I and II were evaluated using the half-scale rule in 
the SF-36 scoring software, according to the manual SF-35 4.0 
211
. Further improvements 
have been made in the SF-36 software 5.0 
212
 concerning missing items, and these were used 
in Study III. In this version, scores are estimated when the respondent has provided a 
response to at least one item on a scale. The only exception is the Physical Functioning (PF) 
scale where item response theory was used to develop a model for estimating a score on PF 
scale. The PF scale differs from the other scales in having different amounts of physical 
activity asked for in the different questions, from vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports, to bathing or dressing yourself, and thus 
another method for calculating missing scores is used 
212
. 
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Missing data in the study-specific questionnaire were evaluated according to the half-scale 
rule according to thyroid-related symptoms. If half of the items were answered, the question 
was included into the analysis. Otherwise the answers were excluded and thus missing. 
4.7 DATA ANALYSES 
4.7.1 Statistical methods 
The statistical methods used in the thesis are listed in Table 1. Patient characteristics were 
described by standard descriptive statistics. 
Comparisons 
In Studies I and II, the mean scores of the transformed SF-36 scores were calculated and 
presented with standard deviation (SD). Statistical significance was tested using the Mann-
Whitney U-test in comparisons of two groups and Kruskal-Wallis when three groups were 
compared. In all calculations, the level of significance was 0.050. In Study I, the results of 
SF-36 were compared with an age- and sex-stratified Swedish general population and 
statistical significance was examined with one sample t-test. 
In Study III, mean scores were calculated and presented with confidence intervals (CI). 
Statistical significance was tested using the Mann-Whitney U-test or Kruskal-Wallis test in 
comparisons between two and three groups, respectively. In all calculations, the level of 
significance was 0.050. In addition, the Wilcoxon signed-rank test at the 0.050 significance 
level was used when comparing SF-36 measurements between diagnosis and one-year of 
follow-up, when the patients in both groups were the same. 
In Studies I-III, in all comparisons including SF-36, a difference of 5-10 points (scale 0-100) 
between groups was interpreted as a clinically relevant, minimally important difference 
(MID), a difference of 10-20 points as a moderate difference, and >20 points as a 
considerable difference 
118
. 
Multivariate regression models 
In Studies II and III, SF-36 responses were dichotomised into “good and “poor”. Logistic 
regression models were used to assess associations in the form of odds ratios (OR) with 
confidence intervals (CI) between “good” and “poor” HRQoL levels. In Study II the aim was 
to assess a correlation between thyroid-related symptoms and HRQoL. Adjustments were 
made for age, sex, comorbidities, education, and menopause. In Study III the aim was to 
identify factors at diagnosis predictive of HRQoL at one year of follow-up. The results of SF-
36 domains at one-year follow-up were adjusted for age, sex, education, marital status, 
comorbidities, view of life, fear of recurrence, tumour stage and the corresponding SF-36 
domain at diagnosis. 
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4.7.2 Qualitative content analysis 
A qualitative conventional content analysis, as described by Hsieh et al., was chosen as this 
type of design is usually appropriate when existing theory or research literature on a 
phenomenon is limited 
150
.  The analysis was performed by two of the authors (first author 
and co-author PS) as follows:  
1. The interviews were read through several times to become acquainted with, and get a 
sense of, the whole content.  
2. Secondly, they were re-read systematically to identify meaning units, which are 
words or text segments, patterns of meaning, and issues of potential interest with 
reference to the research question. In this study, the focus was on anxiety and 
protective strategies. The segments were also marked with a preliminary code, thus 
this is the initial analysis. A preliminary code is close to the text written in the 
interview.  
3. Next, those segments marked with similar codes were brought together and formed 
meaningful clusters, also called preliminary categories. As far as possible, the actual 
words expressed by the informants were used.  
4. Then, the statements in each preliminary category were scrutinised and compared to 
find the central component, and then fused into categories.  
5. Next, the final categories were compared to avoid obvious overlapping and, in a last 
step, the categories were compared and analysed in order to reveal possible 
relationships or hierarchies between them. 
4.8 ETHICAL APPROVAL 
Ethical approval for all the studies was obtained from the Regional Ethical Review Board in 
Stockholm (DNR 2011/718-31/2, 2011/1847-32 and 2014/1736-32). 
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5 RESULTS 
5.1 STUDY I 
Of 353 eligible individuals, 279 (79%) answered the questionnaires. The vast majority of 
patients (78%) were women, the mean age was 51 years and half of the patients reported one 
or more comorbidities. Surgery was the primary treatment reported by all the patients; a 
further 105 (38%) stated that they had received radioiodine treatment and additionally five 
(2%) reported receiving external radiotherapy. 
5.1.1 HRQoL compared with the general population 
HRQoL scores from SF-36 were compared with an age- and sex-matched Swedish general 
population. The patients showed statistically and clinically significant poorer HRQoL on 
three of eight SF-36 domains: vitality, social functioning and mental health  
(all p-values < 0.001). Interestingly, DTC patients reported significantly better physical role 
functioning compared with the general Swedish population (p < 0.001). This specific domain 
answers questions regarding how much of the time the patients have had problems 
performing work and other activities as a result of their physical health. 
5.1.2 Comorbidities, recurrence and fear of recurrence 
Comorbidities were, as expected, associated with lower HRQoL. Patients with one 
comorbidity reported poorer HRQoL on four of the SF-36 domains compared with those with 
none. Furthermore, patients with at least two comorbidities reported worse HRQoL on all 
eight domains compared with those with none (all p-values < 0.001). All differences were 
also clinically significant.  
Only 19 (7%) of the patients reported a recurrence, which is low compared with the general 
risk of recurrence 
38
. However, as many as 134 (48%) stated that they had a fear of 
recurrence. The HRQoL in those with a recurrence was lower than those without fear of 
recurrence on five of eight domains (p < 0.001-0.049) and, similarly, patients with fear of 
recurrence reported poorer HRQoL than those without fear on five of eight domains  
(p < 0.001-0.002). All these differences were also clinically significant. Patients with 
recurrence had similar HRQOL to those with a fear of recurrence, thus, fear of recurrence 
might be an important cause of decreased HRQoL. 
5.1.3 View of life 
Those 30 (11%) patients who stated that their disease had given them a negative view of life 
reported remarkably poorer HRQoL on all eight domains compared with those who reported 
a positive or unchanged view of life (all p-values < 0.001–0.030). Among the 19 patients with 
a recurrence, 12 (63%) stated that their disease had a positive influence on their view of life 
and only two reported that the disease had negatively affected their view of life, and thus 
recurrence seems to be an unusual cause for a negative view of life. 
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5.2 STUDY II 
The study population in Studies I and II was the same and the patient characteristics have 
been presented previously. The remaining patient characteristics analysed in this study are 
thus presented: the majority (85%) had at least 10 years of education and half of the women 
were pre-menopausal. There was no statistical difference between responders and non-
responders regarding age and sex. 
5.2.1 Thyroid-related symptoms 
Thyroid-related symptoms probably related to thyroid disease or levothyroxine treatment 
were defined as fatigue, sleeping disorders, irritability, lower stress resistance, muscle 
weakness, bodily restlessness, sweating, palpitations and flushes. Those symptoms with a 
probable relationship to a given treatment were; xerostomia, hoarseness, dysphagia, 
numbness in the operation area, and salivary gland problems. The majority (88%) of patients 
reported at least one of these symptoms. Almost half (42%) reported major symptoms, and 
46% reported moderate symptoms. All patients with major thyroid-related symptoms had a 
significantly lower HRQoL on all SF-36 domains compared with patients without these 
symptoms (p < 0.001), both statistically and clinically. Additionally, all the differences were 
>20 points corresponding to a major difference on all domains but physical functioning. The 
HRQoL in patients with moderate thyroid-related symptoms compared with patients with no 
symptoms was significantly lower both statistically and clinically on half of the domains  
(p < 0.001-0.02). 
5.2.2 Symptoms related to thyroid disease or levothyroxine treatment 
Between 35% and 77% of patients (depending on symptom) reported symptoms related to 
thyroid disease or levothyroxine treatment. Regarding each symptom separately, all patients 
with moderate or major symptoms grouped together had significantly lower HRQoL 
compared with patients without that symptom (p < 0.001). All comparisons were clinically 
significant with >10 points difference on all SF-36 scores. When comparing patients with no 
symptoms with major symptoms, the difference was >20 points except for palpitations, 
sweating, and flushes. These differences are regarded as considerable clinical differences.  
The most prevalent symptoms were fatigue, sleeping disorders, and irritability. These 
symptoms affected more than half of the patients, and had a large, negative effect on HRQoL. 
Comparing patients with major and no symptoms, SF-36 scores differed by >20 points, 
corresponding to a clinically considerable difference (p < 0.001). Figure 1 shows the 
differences according to fatigue. 
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Figure 1. Differences in long-term HRQoL measured with SF-36 in DTC patients analysed on 
fatigue. HRQoL in patients without fatigue is compared with HRQoL in patients with moderate and 
major symptoms of fatigue. 
5.2.3 Symptoms related to surgery or radioiodine treatment 
Only a few patients reported symptoms with a possible relation to surgery or radioiodine: 
xerostomia (16%), hoarseness (13%), dysphagia (10%), numbness in the operation area (5%), 
and salivary gland problems (4%). All patients with major symptoms had statistically and 
clinically lower HRQoL on all eight SF-36 domains compared with patients with no 
symptoms (p < 0.001). 
5.2.4 Association between thyroid-related symptoms and patient 
characteristics 
The only patient characteristic associated with thyroid-related symptoms was comorbidity. 
Both those with one and those with two or more comorbidities had significantly more 
thyroid-related symptoms (p < 0.001). There was a clear correlation between thyroid-related 
symptoms and a decrease in HRQoL on all SF-36 domains. A statistically significant 
difference was demonstrated between patients with no thyroid-related symptoms and patients 
reporting major thyroid-related symptoms (p < 0.01). These differences remained after 
adjustment for age, sex, comorbidities, and education. 
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5.3 STUDY III 
In this population-based prospective study, 349 (72%) patients answered the HRQoL 
questionnaires at diagnosis and were thus included. Of those, 250 had fulfilled a follow-up 
time of one year. In total, 235 (94%) had answered the HRQoL questionnaires at the one-year 
follow-up, and were thus included in Study III. The majority was women (70%) and the mean 
age was 51 years, both corresponding to incidence figures. During the first year of follow-up, 
6% were diagnosed with loco-regional recurrences, 4% developed distant metastases and 
another five patients (2%) had abnormal Thyroglobulin-values. 
5.3.1 TSH suppression and HRQoL 
As the suppression of TSH has been suggested as one reason for decreased HRQoL in thyroid 
cancer 
182
 we conducted associations between the level of suppression and HRQoL. The 
majority (79%) had moderate or complete suppression. According to our results, those with 
moderate or complete suppression (TSH<0.1) had even slightly better HRQoL compared 
with the mildly suppressed patients (TSH 0.1-<0.4), with significantly better results on three 
of eight SF-36 domains (physical functioning, role physical and bodily pain), which was 
unexpected. 
5.3.2   View of life, fear of recurrence and recurrence 
Patients with a negative view of life were compared with patients with a positive or an 
unchanged view of life. Those with a negative view of life had a lower HRQoL both at 
diagnosis and at one-year of follow-up on eight and seven SF-36 domains, respectively, and 
the differences were also clinically significant. Fear of recurrence was common and seemed 
to affect HRQoL substantially. The majority of patients had a fear of recurrence both at 
diagnosis (75%) and after follow-up (69%). Those who reported a fear of recurrence “often” 
had a significantly lower HRQoL on five SF-36 domains at diagnosis and on seven domains 
after one year, and the differences were also clinically significant. In addition, those with an 
actual recurrence had a significantly lower HRQoL on seven of eight SF-36- domains. 
5.3.3 HRQoL during follow-up 
As expected, according to previous studies 
47
, HRQoL was higher after one year of follow-
up, with significantly higher levels on six of eight SF-36 domains. One important question is 
which factors at diagnosis can affect HRQoL in the future, while these might be possible to 
affect early in the disease trajectory. In a bivariate analysis, age over 50 years, lower 
education, living alone, comorbidities, a fear of recurrence and HRQoL at diagnosis were 
associated with decreased HRQoL at one year of follow-up on some domains. In the 
subsequent multivariate analyses, only poor HRQoL at diagnosis was predictive of poor 
HRQoL at one year of follow-up for each respective SF-36 domain (p < 0.01). 
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5.4 STUDY IV 
In the last study in this thesis, a qualitative method was used. With the aid of semi-structured 
interviews, patients’ anxiety, fear of recurrence and protective strategies were explored. 
Altogether, 21 patients were interviewed. The majority was women (62%), the mean age was 
49 years and mean time since diagnosis was 4 years (range 3 months-18 years).  All patients 
had been treated with at least thyroidectomy and RAI. Five patients had loco-regional or 
distant recurrences. Categories and sub-categories are shown in Table 2. 
 
Table 2. Categories and sub-categories 
Anxiety 
 Contradictions - hidden anxiety 
 Distrust as a source of anxiety 
Protective strategies 
 Everyday life, routines and strategies  
 Information and control 
 
5.4.1 Anxiety 
Anxiety was not restricted to any particular patient characteristics and physical manifestations 
were mentioned as consequences of anxiety. Several informants, both with and without a 
known recurrence, stated that they experienced anxiety both for the actual disease and also 
for future risks. Anxiety was in addition related to, and triggered by, follow-up procedures 
and temporarily decreased by successful investigations. 
“I am a little anxious before the visits. It is a relief to leave the hospital with positive 
information about the disease. It is good to see the doctor regularly.” 
Some patients minimised anxiety at the beginning of the interview, but later during the 
interview the cancer turned out to be a major trigger of anxiety. This kind of hidden anxiety 
might be difficult to reveal during short consultations and is one of the major difficulties in 
patient-doctor communication.  
Initially: 
“…//I wouldn’t say it [the cancer] affects me.” 
Later in the same interview: 
“…[of course] everything, also my cancer, contributes to my worries.” 
At the end of the interview: 
“It [worries and anxiety over her cancer] is of course present all the time.”  
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5.4.2 Distrust 
Several patients mentioned distrust in the healthcare system as a source of increased anxiety. 
Previous negative experiences were a reason for distrust and the anxiety was aggravated by a 
fear of the possibility that future recurrences would be delayed in being detected.  
“What happens if they don’t detect the next recurrence, they don’t know where or how they 
should look for the recurrence…?”  
In addition, a perceived lack of information increased anxiety, and the feeling of not being 
told the whole truth about the disease or investigations also added to the patients’ feelings of 
anxiety. 
…//“Why are they not telling me [about the results of examinations] or do they not want to 
tell me?” “What are they looking for or what are they worried about?” 
5.4.3 Protective strategies 
To decrease anxiety, everyday life and routines worked as important strategies to prevent 
frightening thoughts of the disease. Patients described the need of a “vacation” from the 
cancer and avoiding contact with the healthcare system for some periods of time helped them 
gather energy to cope with their disease. 
“I try to avoid thoughts about the cancer. It is important to have these everyday routines, and 
to have people around me who I like and who like me.” 
In addition, information was an important factor for coping with the cancer. Patients 
described the need of clear-cut and honest information and receiving test results immediately 
was experienced as being important. On the other hand, the method of receiving the 
information was difficult. Telephone calls allow fast communication but, on the other hand, 
make it difficult to prepare questions.    
“…The treatment has been exactly as the doctor told me…//…the information was exact, 
which I think is fantastic. [It was] very, very good information.” 
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6 DISCUSSION  
In this thesis we have studied HRQoL in thyroid cancer patients, both during short- and long-
term follow-up. To explore HRQoL we analysed how patient characteristics, side-effects and 
symptoms were associated with HRQoL. As a complement to the quantitative perspective, 
we further made semi-structured interviews to deepen the understanding about anxiety and 
fear of recurrence. In this discussion, the general findings and interpretations are presented 
first, followed by clinical implications. Finally, the methodological aspects will be discussed.   
6.1 FINDINGS AND INTERPRETATIONS 
6.1.1 HRQoL in thyroid cancer patients during follow-up 
In Study I, long-term HRQoL was measured in a population-based manner. The results were 
compared to a Swedish general population consisting of more than 4000 patients. The 
HRQoL in DTC patients was still lower compared with the general population, despite many 
years of follow-up and a low percentage of recurrences. These results are in good 
concordance with previous studies 
172-174
, although HRQoL similar to a general population 
has been shown in some studies 
175,176
. The causes for the decreased HRQoL are probably 
multidimensional and might be related to the actual cancer itself, but the treatment and side-
effects from levothyroxine could also be of importance. Interestingly, HRQoL in thyroid 
cancer is comparable to that of other cancer patients with even worse prognosis 
177
, which 
suggests that the disease is indeed one reason for the decreased HRQoL.  
In Study III, HRQoL was measured at diagnosis and after one year of follow up. HRQoL was 
higher at the one-year follow-up, which was expected due to the timing of the first 
questionnaire. Similar results, with an increasing HRQoL during the first year have been 
demonstrated in previous studies 
47,171
. The higher HRQoL after one year was probably 
related to a real improvement, but could be affected by a response shift. A response shift has 
previously been shown to affect HRQoL in cancer patients 
213
 and could complicate 
interpretation of the results.  
One of the aims in Study III was to find factors at diagnosis predicting HRQoL during 
follow-up. Predictive factors could help the healthcare system to identify patients with the 
greatest needs and to offer interventions early in the disease trajectory. The only predictive 
factor for all SF-36 domains was the corresponding domain at diagnosis, and the results 
remained after adjustments for confounding factors. In the literature, personality is shown to 
be an important aspect affecting HRQoL 
214
 and could be one explanation for the predictive 
value of HRQoL at diagnosis. This is further supported by our findings in Studies I and III, 
where patients’ with a negative view of life had significantly lower HRQoL, indicating that 
personality traits could be important for HRQoL.  
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6.1.2 Thyroid-related symptoms 
In Study III, thyroid cancer patients reported several symptoms significantly affecting their 
HRQoL. The most common symptoms were fatigue, sleeping disorders, and irritability 
affecting 57-77% of the patients. In the literature, fatigue has been demonstrated to be the 
most frequent symptom in thyroid cancer patients 
173,193,197
 and it is significantly more 
common than in the general population 
188
. In addition, fatigue in thyroid cancer is at least as 
frequent as in other cancers 
189
. Three different methods of decreasing fatigue have been 
investigated in thyroid cancer patients: TSH restoration to non-suppressive doses 
184
, a 
combination of T3 to T4 treatment compared with traditional T4 treatment 
215
 and, exercise 
187
. 
Only exercise has been shown to decrease fatigue. The mechanisms of cancer-related fatigue 
are partly unknown, but inflammatory components play a role 
216
. The effect of physical 
activity might be related to the known anti-inflammatory effect of exercise 
217
. As physical 
activity has been shown to decrease fatigue in both thyroid and other cancer patients 
218
, this 
might play an important role in thyroid cancer rehabilitation in the future. 
In addition to fatigue, sleeping problems are reported as one of the most frequent symptoms 
in thyroid cancer 
173,196,197
. Both in comparisons with a general population and healthy 
controls, thyroid cancer patients have significantly more sleeping disturbances 
173
. Sleeping 
problems are frequently reported in cancer patients in general 
219
 and also co-exist with 
fatigue and tiredness during the daytime 
220
. Suggested causes for the sleeping problems are 
cancer treatments but also the disease itself, and distress and a fear of recurrence can 
aggravate the symptoms 
221
. A recent randomised trial showed a positive effect of exercise on 
sleep quality in breast cancer patients 
222
, and this makes physical activity even more 
appealing in cancer rehabilitation. 
Study II showed, that thyroid cancer patients still, more than 10 years after diagnosis, 
suffered from many thyroid-related symptoms, including fatigue and sleeping disturbances. 
Those with symptoms had significantly worse HRQoL and the impact on HRQoL remained 
after adjustments for common confounders such as age and comorbidities. This study 
highlights the importance of carefully asking patients about symptoms and, if possible, they 
should be offered help with treatable symptoms.  
6.1.3 TSH and HRQoL 
In Study III the relationship between TSH suppression and HRQoL was investigated. After 
one year of follow-up, the majority of patients were under moderate or complete TSH 
suppression. We demonstrated that these patients had better HRQoL compared with those 
with mild suppression, and were similar to those with no suppression. These results support 
previous findings that TSH suppression is not correlated with decreased HRQoL 
185
. In 
addition, restoration to normal TSH does not increase HRQoL 
184
. Although TSH does not 
seem to be associated with a decrease in HRQoL, patients still have significant levels of 
symptoms often seen in hyperthyroidism. One suggestion for our findings is that those 
patients with mild suppression could have had pronounced symptoms from complete TSH 
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suppression. Therefore, they might have been prescribed lower doses of levothyroxine to 
decrease these symptoms.  
Another aspect of TSH suppression is the correlation with an increased risk of cardiovascular 
mortality 
60
 and osteoporosis 
61
 in thyroid cancer patients with lower TSH values. 
Consequently, there might still be unknown hormonal factors that could explain both thyroid-
related symptoms and cardiovascular morbidity.  
6.1.4 Fear of recurrence 
In Studies I and III fear of recurrence was reported by more than 70% of the patients during 
diagnosis and almost half of the patients throughout follow-up. Fear of recurrence and fear of 
developing another cancer were also important findings in the interviews in Study IV. In 
addition, fear of recurrence was associated with a significantly decreased HRQoL, and is thus 
an important factor for the patients’ well-being.  
Despite the good prognosis, thyroid cancer patients have similar levels of fear of recurrence 
when compared with other cancer patients 
134
. This can partly be explained by the remaining 
life-long risk of recurrence, which most patients should be aware of. Younger patients, 
having children, a shorter time from diagnosis and suspected or proven recurrence are factors 
associated with fear 
223
. Interestingly, these are mostly the same factors which are associated 
with lower HRQoL 
178
. The life-long treatment with levothyroxine and the follow-up visits 
may add to the fear.  
One important aspect could be the experience of having a “good cancer”, which has been 
reported in qualitative studies 
201,202
. As a consequence of this “good cancer”, patients 
experience their disease to be trivialised, and they do not feel they have the right to 
psychosocial support. This might make the coping process more complicated and add to their 
fear. 
6.1.5 Anxiety 
In Study IV, anxiety was described by the majority of the patients, regardless of disease 
stage. Anxiety is known to be common in cancer patients, both in those cured from their 
disease and in patients with metastases 
141,143
. Surprisingly, anxiety and depression are higher 
in thyroid cancer compared with several other cancer diagnoses with a poorer prognosis 
144
. 
From a physician’s point of view, DTC has an excellent prognosis and is often communicated 
to the patients as a “good cancer” 201,202. To be diagnosed with a cancer can be considered a 
death threat and the term “good” is, for them, conflicting when it appears to invalidate their 
fears of having a cancer 
202
. The need for long-term follow-up might add to the anxiety and, 
in our study, follow-up procedures were mentioned as one source of anxiety. The increasing 
distress around planned follow-up is shown in several cancer diagnoses 
224,225
 and the follow-
up visits remind the patients of their disease, thus increasing anxiety. In Study IV, anxiety 
was also associated with a fear of recurrence and, in addition, persistent Tg values. Tg is a 
sensitive tumour marker and important for monitoring the disease. However, in patients with 
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persistent Tg, the frequent follow-ups of abnormal laboratory tests might be a source of 
severe anxiety.  
One important finding was the partly hidden anxiety, when patients denied anxiety at the 
beginning of an interview, but then admitted it later on. These kind of contradictions have 
been shown earlier, when patients denied anxiety one moment, but then openly talked about 
death anxiety in the next sentence 
226
. This could be of great importance in the clinical setting, 
when consultations are often short and hidden anxiety might be missed. During consultations, 
patient-physician communication is predominantly concerned with medical issues, and 
symptoms and anxiety are discussed to a lesser extent 
227
. This highlights the importance of 
also focusing on anxiety and other symptoms especially in thyroid cancer patients, who both 
might deny anxiety and also feel they do not have the right to complain about it due to the 
good prognosis.  
Lack of information was mentioned as one source of anxiety in Study IV. Some patients felt 
that doctors gave evasive answers to their questions and, in addition, did not share with them 
the whole truth about their disease. Others mentioned that communication regarding test 
results was a problem, that a delay in receiving the results was increasing their anxiety. 
Previous studies have shown that unmet information needs are a frequent problem in thyroid 
cancer 
228
 and, on the other hand, those patients who are satisfied with their information needs 
experience less distress 
229
. In Study IV, good information was described as an important part 
of coping with the disease. Clear-cut information created a sense of control, which resulted in 
decreased levels of anxiety. To ask the patients what kind of information they wish to receive 
and how they want it to be delivered could probably decrease their anxiety. 
6.2 CLINICAL IMPLICATIONS 
Based on the results in our studies, how can we help Lena, the 40-year-old woman with 
increasing anxiety before her follow-up visits? 
According to our findings, patients with DTC have several reasons for anxiety and decreased 
HRQoL; fear of recurrence, lack of information, thyroid-related symptoms, and a life-long 
need of follow-up. All these factors could increase Lena’s anxiety. In the first place, she 
should be offered a consultation with the physician responsible for her treatment, as a good 
patient-physician relationship is vital for communication. The visit should not address 
medical issues alone, but also her anxiety and fears. In addition, possible thyroid-related 
symptoms affecting her HRQoL should be discussed as, for example palpitations and 
sleeping disorders could be possible to treat.  
As DTC patients might not have been offered psychosocial support during the disease 
trajectory due to the “good cancer” perception, this should be offered to Lena. Adequate 
information about the favourable prognosis is obviously important, but to normalise her fears 
and anxiety could help Lena cope with her disease. The term “good cancer” should be 
avoided, and instead the term low-risk cancer is an option. 
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What kind of follow-up should Lena be offered? Lena is frightened and anxious before visits 
and appears to have a low-risk cancer. Thus, she could be offered individualised follow-up 
with less frequent visits and laboratory tests replacing some follow-up visits. If telephone 
calls are offered for test results, then it is crucial to offer answers in a timely fashion.  
How can the initial care be organised to avoid anxiety? Adequate information about the 
prognosis without using the term “good cancer” is vital. To offer psychosocial support early 
on could be recommended, but unfortunately no good predictive tools for patients at risk of 
decreased HRQoL or anxiety exist. Thus, good patient-physician communication allowing 
patients’ psychosocial needs to be addressed during consultations could be one possibility of 
decreasing anxiety. 
6.3 METHODOLOGICAL CONSIDERATIONS 
6.3.1 Internal validity 
In quantitative studies, validity is important to assess and internal validity is defined as how 
well the study results have been measured, that is, the absence of systematic errors. 
Systematic errors do not decrease if the sample size is increased, as the errors remain during 
measurements. On the contrary, random errors are reduced by increasing the sample size. 
Systematic errors are often called bias, and are divided into three main groups; selection bias, 
information bias and confounding 
230
.  
Selection bias  
Selection bias refers to the differences between study participants and non-participants, thus 
the participants are not representative of the whole target population. Because the difference 
is unknown, the selection bias cannot be observed but is suspected 
231
. 
Studies using postal questionnaires are inexpensive in gathering data, but non-responders are 
a problem and decrease the accuracy of the data. Several ways of increasing participation 
exist; people can be contacted in advance, questionnaires can be sent by first class post, 
questionnaires can be made personal and kept short, compensation can be offered and 
reminders can be sent 
232
. In Studies I, II and III most questionnaires were posted, and up to 
three reminders were sent to non-responders. The included letter was easy to understand and 
a pre-paid return envelope was enclosed. No compensation was offered. It is known that 
lower response rates are expected among men, younger, and rural inhabitants 
233
. In Studies I 
and II the inclusion was population-based and there was no statistical difference between 
responders and non-responders regarding age and sex. However, in Study III, non-responders 
were younger (mean age 43 vs 51 years, p = 0.03) but with no difference in sex. Younger 
patients could have had better physical functioning, which might have affected the results. In 
Study III, the hospitals including patients did not start inclusion into the study at the same 
time. Thus, all eligible patients during the time period were not included. Patients were, 
however, included from all Swedish hospitals administering RAI treatment to DTC patients, 
and all disease stages, different age groups, and patients from both cities and rural areas were 
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included. Loss-to follow-up was extremely low in Study III, with a response rate of 94% at 
the one-year follow-up. In Study IV, although it was a qualitative study and no statistical 
methods were used, it is worth mentioning that no patients refused to participate. 
Information bias  
Information bias, also called misclassification bias, is due to errors in collecting information 
from, or about, study subjects. 
In Studies I and II, all the data was filled in by the patients, that is, sociodemographic factors, 
comorbidities, treatments and symptoms. There may have been possible information bias due 
to recall bias or because the patients could not understand the questions. To minimise 
language difficulties, the questionnaire was pilot tested on five patients, and no difficulties 
appeared.  Regarding comorbidities, self-assessment has shown high concordance with 
medical records, and the method is therefore acceptable 
234
. According to recommendations, 
no healthcare providers helped the patients to complete the questionnaires, but no information 
is available about possible family members or others helping them 
81
. Information from 
medical records in Study III was obtained on a predefined protocol developed by the research 
group. All the medical records were reviewed by the first author to minimise 
misclassification.  
At the beginning of our studies, no validated HRQoL questionnaire suitable for thyroid 
cancer patients was available in Swedish. Therefore, two different questionnaires were used, 
the SF-36 and the study-specific questionnaire. SF-36 is a well-validated HRQoL instrument, 
but does not include questions regarding specific thyroid cancer issues. While thyroid cancer 
patients are not expected to have typical symptoms from chemotherapy, radiotherapy, or 
other oncological treatments, a general HRQoL questionnaire was regarded as suitable. SF-36 
is regarded as valid for the use in studies of thyroid cancer patients 
45,47,112
. The study-specific 
questionnaire is not validated, but includes questions relevant for thyroid cancer patients, 
including questions about symptoms and side-effects from the disease and given treatment. 
The questionnaire was developed by the research group, with its relevant knowledge of 
thyroid cancer and its symptoms. Recently, a phase III study has investigated an EORTC 
QLQ-C30 thyroid-specific module THY34 
235
, and as soon as it is validated in a phase IV 
study and translated to Swedish it should be a good alternative. 
Confounding 
Confounding refers to a “confusion of effects”, that is, finding an association of the wrong 
reason. A confounder is a factor interfering with both the exposure and the outcome, but not a 
causal factor. Randomisation and matching are methods of preventing confounding. In 
addition, adjustments for known confounders can be analysed statistically 
230,231
. 
In Studies II and III, adjustments were discussed in the research group and the statistical 
method was discussed with a statistician. To accomplish adjustments SF-36 domains were 
dichotomised into “good” versus “poor”. Patients answering “no” or “little” 
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symptoms/impact on HRQoL on all questions on one domain were categorised as having 
“good” HRQoL. They were otherwise categorised as having “poor” HRQoL. Multiple 
logistic regression models were used to adjust for confounding factors. The dichotomisation 
has not been validated, however, as the aim was to compare patients with no/few symptoms 
with those with more symptoms, the method seemed acceptable. 
6.3.2 Random errors and precision 
Random error is the influence of chance, thus referring to the variability in the data and 
providing information about the precision. Random errors can be estimated by confidence 
intervals (CI) and tested with p-values, that is, the analysis of significance. A commonly used 
CI is 95%, which is, if the study was to be repeated many times, for 95% of the time the CI 
would include the correct values of the measure. The width of the CI is related to the 
variability, and aids the investigator in deciding whether the difference is of clinical 
importance. The p-value is calculated from the same equation as the CI and measures 
whether the null hypothesis, which states that there is no relation between exposure and 
outcome, is true or not. The p-value answers the question: what is the probability to receive 
this result, or a more extreme one, if the null hypothesis is true? In medical research, a p-
value of < 0.05 is commonly used as a significant level, although it is more of a convention 
and other possible levels such as < 0.01 or < 0.001 could be used 
231
. 
No statistical testing is completely certain and there is always, therefore, a risk of errors being 
made. A Type I error occurs when a null hypothesis is rejected although it was true (false 
positive). On the contrary, a Type II error is when the null hypothesis is not rejected although 
it is false (false negative). The risk of Type I errors can be decreased by lowering the p-values 
and to decrease the risk of Type II errors a larger study population is needed. Another 
measure is power, which is 1-Type II error. Power is the probability of obtaining a 
statistically significant p-value when the null hypothesis is truly false 
231,236
. 
In our studies we have set the level of a significant p-value to < 0.05, which might generate 
many significant p-values due to multiple testing. To add a clinical significance to the results, 
MID was used and no differences in SF-36 <5 points were regarded as significant. To reduce 
Type II errors the sample size in Studies I, II and III was more than 200 patients and the 
power is, therefore, satisfying. 
6.3.3 HRQoL measurements 
To assess HRQoL, the most appropriate questionnaires should be used. Generic instruments 
might not capture symptoms relevant for certain diseases, while disease-specific instruments 
could be complemented with a general questionnaire to better understand HRQoL changes 
over time. In addition, specific questions about certain symptoms, fears or life satisfaction 
could be added depending on the study 
77
. By using the study-specific questionnaire as a 
complement to SF-36, disease-specific questions were added, when no disease-specific 
questionnaire was available. In addition, to address two clinically important questions not 
included in other instruments, fear of recurrence and change in view of life were added.  
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Scoring 
The questions in SF-36 are answered on an ordinal scale with three to six response 
alternatives and transformed to a scale ranging from 0-100. The transformation could be 
questionable, while certain answers can only become specific numbers from 0-100. If a larger 
number of response categories are offered, respondents tend to choose different answers 
during repeated testing and, thus, four to five response categories are recommended. In SF-
36, all the questions are multi-item, that is, the same domain is composed of several 
questions, and this gives a greater precision. 
In the study-specific questionnaire we have used five response categories for the symptoms 
related to thyroid disease or levothyroxine treatment and three for the treatment-related 
symptoms. When measuring associations between symptoms and SF-36, the answers were 
grouped together into three categories: corresponding to “no”, “moderate” and “major” 
symptoms.  These three groups show clear-cut differences in HRQoL levels.  
The questions about symptoms and side-effects can be discussed, at least after studies 
investigating and developing the EORTC QLQ-C30 THY34 disease-specific questionnaire 
235
. Some of the questions are lacking in our disease-specific questionnaire used in Studies I, 
II and III, partly because we only intended to study specific symptoms and not the life impact 
of the disease. On the other hand, although we have fewer questions in our questionnaire, 
they cover important parts of the THY34 questionnaire. In addition, the symptoms-specific 
questions seem relevant, because the different levels with “no”, “moderate” and “major” 
symptoms have significantly effect on the SF-36 domains. Moreover, the question regarding 
fear of recurrence showed similar associations to SF-36, where those with “often” had lower 
HRQoL compared with those reporting “seldom” and “no” fear of recurrence. Although 
fewer patients had a negative change in view of life, those reporting negative view had 
significantly lower HRQoL, making the question important. 
Clinical significance 
In medical research, p-values < 0.05 are often assessed as significant, but in HRQoL 
measurements, in addition, clinical significance is of great importance to the patients. 
Although the concept of QoL is understood by the readers, an understanding of the 
measurements in HRQoL studies is seldom well known to clinicians. Thus, reporting HRQoL 
data should include both statistical and clinical significance reported in a clear-cut way. 
A difference of 5-10 points on a 100-point scale is often regarded as clinically significant 
118
. 
There seem to be differences in the ability to experience improvement and deterioration of 
HRQoL. An improvement of 5% might be meaningful, whereas a 10% decline is required to 
be clinically significant 
237
.  
In our studies we have used 5-10 points as a small clinical significance, 10-20 as a moderate 
and >20 as a major difference. In measuring HRQoL during the follow-up in Study III, which 
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was increasing, the results should be clearly clinically important according to the lower 
required difference during improvements of HRQoL.   
Response shift 
Patients experiencing a serious illness learn to adapt to and cope with their disease and often 
report better HRQoL than expected, which is understood as a response shift. Clinicians are 
aware that their patients are adapting to their disease, but in HRQoL research it is difficult to 
take this into account. In Study III, HRQoL was measured at the time of diagnosis and after 
one year of follow-up. The increasing HRQoL during the first year might be affected by a 
response shift and thus overestimated, and the interpretation of the results is therefore 
challenging. 
6.3.4 External validity 
External validity refers to what extent the results from a study can be generalised to another 
population 
231
. In Studies I and II, the inclusion was population-based and no differences 
according to age and sex were measured between the responders and non-responders. Thus, 
these results could be generalised to another thyroid cancer population in a country with a 
similar a healthcare system. The long follow-up time makes the results comparable to a large 
group of patients due to the longevity of the disease. However, the treatment and follow-up of 
thyroid cancer is changing, which makes the results more difficult to compare in patients with 
a shorter follow-up time. In addition, few recurrences were reported and the results cannot be 
generalised to patients with recurrent disease. In Study III, the inclusion was population-
based, although it might be expected that more patients from urban areas were included and, 
in addition, non-responders were younger. The population-based inclusion does, however, 
offer generalisation to thyroid cancer patients with short-term follow-up, but not to other 
forms of cancer. 
6.3.5 Trustworthiness 
Corresponding to the terms validity and reliability in quantitative studies, the term 
trustworthiness is used in qualitative research. It is an assessment of how the study results can 
be trusted and if the findings are worth paying attention to. The terms used for 
trustworthiness are credibility, dependability and transferability 
156
. In Study IV, we did take 
into account some important aspects of trustworthiness.  
Credibility 
Credibility assesses how well the data collection and the analysis process address the research 
question 
156
. The aim of the study was to capture and describe the experience of thyroid 
cancer in depth, to find the variation and also the most common patterns. To increase 
credibility, patient selection was made by purposeful maximum-variation sampling according 
to age, sex, stage of disease, education, and time since diagnosis; to capture the width of the 
experience by as broad an inclusion as possible. To ensure that the most common themes 
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were covered, saturation was assessed, that is, no new data was discovered after 15 
interviews. Another six interviews were conducted to ascertain that no new information could 
be found. We did not include patients with smaller tumours. These individuals could be 
expected to have similar experiences of their disease, due to our results showing that disease 
stage did not affect HRQoL.  
The method of analysis is another aspect of credibility. In our study, we have shown the 
different steps used during the analysis according to Hsieh 
150
. While defining meaning units 
we have used the exact words from the interviews not to lose any meaning. In addition, 
dialogical intersubjectivity was aimed at 
151
, meaning that the authors analysed relevant 
interview segments separately and compared their findings. In case of any discrepancies, 
these were discussed, revised, and validated in discussion with the other author. To enable 
readers to judge similarities and differences between categories, representative quotations 
from the text were shown. During analysis for Study IV, the most apparent and common 
themes were anxiety and protective strategies. Thus, the analysis and reporting is based on 
those results. Those results not reported are therefore unknown for the readers, might contain 
aspects of interest. To avoid uncertainty, the method and the chosen themes were described in 
the paper for Study IV.    
Dependability 
Dependability refers to which codes and quotations are included in the categories. While data 
collection extends over time, and the interviewing is an evolving process, the interviews can 
be affected by the researchers. To ensure that the analysis is consistent, several researchers 
can cooperate 
156
. In Study IV, several interview segments were analysed by two of the 
researchers, to ensure that the analysis was consistent and that different opinions were 
discussed. The aim was not to reach a consensus, but to find possible alternative 
interpretations. 
Transferability 
Transferability refers to what degree the findings in a qualitative study can be applied beyond 
the bounds of the project, and is similar to external validity in quantitative research. To 
enable the readers to judge transferability the method section importantly contains a clear 
description of the context in which the study was carried out, participant selection criteria 
used, and a clear description regarding the analysis 
156
. For Study IV, patient selection is 
clearly described and, in addition, a description of where the interviews were conducted and 
methods of analysis were provided. For readers, the transferability is difficult due to different 
healthcare systems, varying follow-up routines and other cultural expressions when dealing 
with crisis and anxiety. 
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7 CONCLUSIONS 
Some conclusions that can be drawn from the studies in this thesis 
 Long-term HRQoL in patients with DTC is lower compared with the general 
population measured 14-17 years after diagnosis. 
 
 Half of the patients have a fear of recurrence both at diagnosis and during long-term 
follow-up. 
 
 Thyroid-related symptoms affect, depending on symptom, 35-77% of thyroid cancer 
survivors, and these symptoms affect HRQoL negatively. 
 
 Negative view of life affects HRQoL significantly. 
 
 Short-term HRQoL increases during the first year of follow-up. 
 
 TSH-levels do not seem to affect HRQoL in DTC patients. 
 
 HRQoL at diagnosis is a predicitive factor for HRQoL during follow-up. 
 
 Anxiety is a major concern for thyroid cancer patients. 
 
 Protective strategies help patients to cope with their anxiety. 
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8 FUTURE RESEARCH 
Decreased HRQoL in thyroid cancer patients both at diagnosis and during follow-up is an 
important finding in this thesis. These patients have a significant symptom burden and 
increased anxiety affecting their HRQoL. In order to assess further information about how 
HRQoL develops over time, a follow-up of the prospective study is warranted. We are 
continuously gathering data from the patients included in Study III and, follow-up is planned 
both at three and five years after inclusion. These data will provide a further insight into the 
development of HRQoL over time. As population-based follow-up results are not, to the best 
of our knowledge, yet published, this will contribute substantially to the understanding of 
HRQoL in DTC patients. During follow-up a careful review of medical records is made, 
enabling further exploration of tumour characteristics, treatment-related factors, and 
laboratory tests affecting HRQoL. One of the most interesting findings will be the effect of 
TSH values on medium-term HRQoL. 
In the qualitative study, increased anxiety and different ways of coping with the cancer were 
major findings. Several patients experienced anxiety related to follow-up visits. To further 
investigate these findings, additional interview data is available. Further qualitative analyses 
of the patient-physician relationship and the patients’ experiences of healthcare could give 
important insights both into their thoughts and attitudes about their disease and its treatment, 
and also about their opinions concerning the healthcare system. 
Further, the question not answered is how personality affects HRQoL and how patients in the 
greatest needs are offered help. Our intention is to find a predicitve tool for decreased 
HRQoL at diagnosis and offer those patients psychosocial counseling. The best possible 
study would be a randomised trial offering counseling and structured information to DTC 
patients in combination with thorough measurements of HRQoL and distress over time. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
9.1 BAKGRUND 
Sköldkörtelcancer, eller tyreoideacancer, utgör endast 1 % av alla cancerfall i Sverige, men är 
en av de snabbast ökande cancerformerna. Ungefär 3 av 4 som drabbas är kvinnor och 
medelåldern vid insjuknandet är under 50 år, alltså betydligt lägre än vid de allra flesta 
cancersjudomar. De två vanligaste typerna av tyreoideacancer är den papillära och den 
follikulära, som tillsammans utgör den differentierade tyreoideacancern. Härefter används 
tyreoideacancer i betydelsen differentierad tyreoideacancer.  
Tyreoideacancer har en mycket god prognos med en överlevnad på över 90 % och i 
kombination med tidigt insjuknande är det många som lever med sjukdomen. Sjukdomen 
upptäckts oftast som en knöl på halsen. Behandlingen består av operation, där sköldkörteln 
och ibland även närliggande lymfkörtlar, avlägsnas. Som efterbehandling ges ofta radioaktivt 
jod, vars syfte är att avlägsna eventuella kvarvarande cancerceller. När patienterna har 
opererat bort sin sköldkörtel, kommer de att behöva livslång medicinering med 
sköldkörtelhormon. Behandlingen av tyreoideacancer har relativt få biverkningar, som inte är 
jämförbara med andra cancerbehandlingar såsom cellgifter eller strålbehandling. Prognosen 
för patienter med tyreoideacancer är mycket god. Således förväntas sjukdomen ha en liten 
inverkan på patienternas livskvalitet. 
Flera tidigare studier har visat att patienter med tyreoideacancer trots detta har sämre 
livskvalitet än normalbefolkningen. De har ungefär motsvarande livskvalitet som andra 
cancerpatienter, trots att prognosen vid tyreoideacancer ofta är påtagligt bättre. En stor andel 
av patienterna med tyreoideacancer har oro för återfall, vilket påverkar deras livskvalitet 
negativt. Eftersom prognosen är så bra, har sjukvården en tendens att klassa den som en 
”snäll cancer”. Det kan uppfattas av en del som något positivt, men många upplever det som 
jobbigt. Att få en cancersjukdom är livsomvälvande oberoende av om prognosen är god och 
om sjukdomen är ”snäll”. Patienterna kan uppleva att de inte får samma typ av psykosocialt 
stöd som andra cancerpatienter och de känner att deras rädsla inte blir tagen på allvar p.g.a. 
den ”snälla cancern”.  
Således drabbas dessa patienter av försämrad livskvalitet, men varken orsaken till den 
försämrade livskvaliteten eller hur den utvecklas över tid är klarlagt. Syftet med denna 
avhandling var att studera hur livskvaliteten hos patienter med tyreoideacancer ser ut och hur 
den utvecklas över tid och därtill att identifiera faktorer som påverkar livskvaliteten på kort- 
och långsikt. 
9.2 METOD 
När man studerar livskvalitet relaterat till sjukdom och de symtom som beror på sjukdomen, 
kallas detta för hälsorelaterad livskvalitet. Hälsorelaterad livskvalitet mäter hur sjukdomen 
påverkar patienternas fysiska och psykiska hälsa samt hur deras förmåga att utföra dagliga 
aktiviteter påverkas. Livskvalitet mäts oftast med frågeformulär. Dessa frågeformulär är olika 
 50 
 
utformade beroende på syftet med studien. Generella formulär mäter livskvalitet hos patienter 
med olika sjukdomar och även friska människor, vilket innebär att jämförelser kan göras 
mellan olika patientergrupper och med normalbefolkningen. Sjukdomsspecifika formulär är 
utformade för att mäta symtom som är specifika för vissa sjukdomar.  
Denna avhandling omfattar fyra delarbeten. I delarbete I, II och III har vi studerat livsvalitet 
med frågeformulär och i delarbete IV har vi intervjuat patienter. Då patienter med 
tyreoideacancer inte förväntas ha samma symtom som andra cancerpatienter, har vi i denna 
avhandling använt ett generellt frågeformulär, som kallas SF-36. Som komplement har vi 
utvecklat ett eget studiespecifikt frågeformulär för att mäta de symtom och biverkningar som 
kan uppkomma efter behandling av tyreoideacancer.  
I delarbete I och II har vi skickat frågeformulär till patienter med tyreoideacancer 14-17 år 
efter diagnos, för att studera deras livskvalitet på lång sikt. I delarbete III har vi inkluderat 
patienter vid diagnos och följt dem efter ett år, då de svarat på samma frågeformulär som i 
delarbete I och II. I delarbete IV genomförde vi intervjuer med 21 patienter för att ytterligare 
öka kuskapen om hur patienter med tyreoideacancer mår. 
9.3 PATIENTER OCH RESULTAT 
Delarbete I och II 
I delarbete I och II har vi inkluderat 279 patienter med tyreoideacancer. Dessa hade sämre 
livskvalitet jämfört med en jämförande grupp från den svenska befolkningen. Därtill hade 
hälften av patienterna oro för återfall, trots många år sedan diagnos. De patienter som hade 
oro för återfall hade påtagligt sämre livskvalitet än de utan oro. 
I delarbete II har vi undersökt vilka symtom dessa patienter lider av. Majoriteten av 
patienterna hade symtom som skulle kunna vara relaterade till den cancerbehandling de fått 
och det sköldkörtelhormon som alla patienter får. De vanligaste symtomen var trötthet, 
sömnsvårigheter och irritationskänsla. De patienter med symtom hade påtagligt sämre 
livskvalitet än de utan symtom. Eftersom symtomen kunde bero på många andra faktorer än 
sjukdomen, som ålder, kön, andra sjukdomar och cancers allvarlighetsgrad, gjordes 
ytterligare statistiska analyser. Analyserna visade att den negativa inverkan på livskvalitet av 
trötthet, irritationskänsla och sömnssvårigheter faktiskt berodde på dessa symtom och inte på 
andra faktorer.   
Delarbete III 
I delarbete III inkluderades 235 patienter i samband med att de fick sin cancerdiagnos. Deras 
livskvalitet mättes vid diagnos och efter 1-års uppföljning. Livskvaliteten förbättrades 
påtagligt under det första året, vilket var förväntat. Majoriteten av patienterna hade oro för 
återfall både vid diagnos och vid uppföljning, vilket påverkade deras livskvalitet negativt. För 
att identifiera om någon faktor vid diagnos kunde förutspå patienternas livskvalitet efter 1 års 
uppföljning analyserades bl.a. följande faktorer: ålder, kön, utbildning, oro för återfall och 
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livsvalitet vid diagnos. Den enda faktorn som vid diagnos kunde förutspå livskvalitet vid  
1 års uppföljning var livskvaliteten vid diagnos. 
Delarbete IV 
För att fördjupa kunskapen om hur oro för återfall och ångest påverkar patienternas 
livskvalitet, utförde vi i delarbete IV intervjuer med 21 patienter. De flesta patienterna, 
oberoende av ålder, kön eller sjukdomens allvarlighetsgrad, upplevde ångest. Denna ångest 
var relaterad till oro för återfall och många upplevde att ångesten ökade i samband med 
återbesök. De flesta patienterna hade strategier för att minska ångesten. Det vardagliga livet 
med arbete och barn hjälpte dem att inte tänka på sin cancersjukdom. Bra och fullständig 
information om sjukdomen och dess behandling gav patienterna en känsla av kontroll och 
hjälpte dem att bearbeta sin sjukdom. 
9.4 DISKUSSION 
Patienter med tyreoideacancer upplever sämre livskvalitet jämfört med en generell population 
i Sverige, trots den goda prognosen. Orsaken är antagligen mångfacetterad, och torde vara 
relaterad till själva cancersjukdomen. Detta stöds av att patienter med tyreoideacancer har en 
likvärdig livskvalitet jämfört med andra cancerpatienter, som har betydligt sämre prognos.  
Majoriteten av patienterna upplevde symtom som trötthet och sömnproblem. Dessa patienter 
hade påtagligt sämre livskvalitet än de utan symtom. Trötthet är det vanligaste symtomet 
även hos andra cancerpatienter men orsaken är inte klarlagd. Många av patienterna hade 
också sömnproblem, vilket kan vara en förklaring till tröttheten. Sömnproblemen förvärras 
ofta av oro relaterat till själva cancersjukdomen, och således är det viktigt att efterhöra 
symtom för att bäst kunna avhjälpa dessa.  
Den livskvalitet patienterna upplevde vid diagnos var den enda faktorn som verkade 
förutsäga hur livskvaliteteten är vid 1 års uppföljning. En förklaring till detta fynd kunde vara 
att personlighet påverkar livskvaliteten. I studier gällande många olika cancersjukdomar har 
man visat att en mera negativ personlighet ger upphov till sämre livsvalitet.   
Många patienter hade rädsla för återfall, både vid diagnos och under uppföljning. Denna 
rädsla är lika vanlig hos patienter med tyreoideacancer som hos andra cancerpatienter med 
betydligt sämre prognos. Oron ger både en försämrad livskvalitet och är också en källa till 
ångest. Denna oro kan förvärras av att patienterna fått höra att de har en ”snäll cancer”, vilket 
gör att deras rädsla och ångest inte tas på allvar. Således är det viktigt att fånga upp 
patienternas upplevelser, och istället för att prata om en ”snäll cancer” kan ordet lågrisk 
cancer användas. Att erbjuda psykosocialt stöd även vid tyreoideacancer är oerhört viktigt, då 
många patienter kan ha blivit negligerade vid diagnos p.g.a. den goda prognosen. 
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12 APPENDIX 
12.1 STUDY-SPECIFIC QUESTIONNAIRE 
